US7767681B2 - 2-Carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof - Google Patents

2-Carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof Download PDF

Info

Publication number
US7767681B2
US7767681B2 US11/649,316 US64931607A US7767681B2 US 7767681 B2 US7767681 B2 US 7767681B2 US 64931607 A US64931607 A US 64931607A US 7767681 B2 US7767681 B2 US 7767681B2
Authority
US
United States
Prior art keywords
group
formula
alkyl
compound
och
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US11/649,316
Other versions
US20070179126A1 (en
Inventor
Pierre Casellas
Daniel Floutard
Pierre Fraisse
Samir Jegham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Assigned to SANOFI-AVENTIS reassignment SANOFI-AVENTIS ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CASELLAS, PIERRE, FLOUTARD, DANIEL, FRAISSE, PIERRE, JEGHAM, SAMIR
Publication of US20070179126A1 publication Critical patent/US20070179126A1/en
Application granted granted Critical
Publication of US7767681B2 publication Critical patent/US7767681B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/40—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof

Definitions

  • the invention relates to 2-carbamide-4-phenylthiazole derivatives, to the preparation thereof and to the therapeutic use thereof.
  • a subject of the invention is compounds corresponding to formula (I) below:
  • R 6 is selected from the group consisting of H, F, (C 1 -C 4 )alkyl, —(CH 2 ) n OH, —(CH 2 ) n O(C 1 -C 4 )alkyl and —(CH 2 ) n NR 4 R 5 , where n represents 0, 1 or 2, and R 4 and R 5 represent, independently of one another, a hydrogen atom, or a (C 1 -C 8 )alkyl, —CO(C 1 -C 4 )alkyl or —CO—O—(C 1 -C 8 )alkyl group;
  • R 7 is selected from the group consisting of H, (C 1 -C 8 )alkyl, —CO—(C 1 -C 8 )alkyl, benzyl, —CO—O—(C 1 -C 8 )alkyl, —CO—O-benzyl, —CO-phenyl, —CO-heteroaryl, —CO—(C 3 -C 10 )cycloalkyl, —SO 2 —(C 1 -C 8 )alkyl, —SO 2 —(C 3 -C 8 )cycloalkyl and —SO 2 -heteroaryl;
  • R 7 is as defined above
  • R 7 is as defined above
  • a preferred halogen is a fluorine.
  • the compounds of formula (I) may contain one or more asymmetric carbon atoms. They may therefore exist in the form of enantiomers or of diastereoisomers. These enantiomers and diastereoisomers, and also mixtures thereof, including racemic mixtures, form part of the invention.
  • the compounds of formula (I) may exist in the form of bases or of addition salts with acids. Such addition salts form part of the invention.
  • salts are advantageously prepared with pharmaceutically acceptable acids, but the salts of other acids that are useful, for example, for purifying or isolating the compounds of formula (I) also form part of the invention.
  • the compounds of formula (I) may also exist in the form of hydrates or of solvates, i.e. in the form of associations or combinations with one or more water molecules or with a solvent. Such hydrates and solvates also form part of the invention.
  • R 1 , R 2 , R 3 and Y are as defined above.
  • Compounds of the invention of formula (I.a) are those in which R 1 is in the 2-position and R 2 is in the 5-position with respect to the phenyl.
  • R 1 , R 2 , Y, p and A are as defined above.
  • Compounds of the invention of formula (I.b) are those in which R 1 is in the 2-position and R 2 is in the 5-position with respect to the phenyl.
  • R 1 , R 2 , Y and B are as defined above.
  • Compounds of the invention of formula (I.c) are those in which R 1 is in the 2-position and R 2 is in the 5-position with respect to the phenyl.
  • protecting group Gp is intended to mean a group that makes it possible, firstly, to protect a reactive function such as a hydroxyl or an amine during a synthesis and, secondly, to regenerate the intact reactive function at the end of synthesis.
  • Examples of protective groups and also methods of protection and of deprotection are given in “Protective Groups in Organic Synthesis”, Green et al., 2nd edition (John Wiley & Sons, Inc., New York).
  • leaving group X is intended to mean a group that can be readily cleaved from a molecule by breaking a heterolytic bond, with a pair of electrons leaving. This group can thus be readily replaced with another group in a substitution reaction, for example.
  • Such leaving groups are, for example, halogens or an activated hydroxyl group such as a mesyl, tosyl, triflate, acetyl, etc. Examples of leaving groups and also references for the preparation thereof are given in “Advances in Organic Chemistry”, J. March, 3rd Edition, Wiley Interscience, p. 310-316.
  • R 1 , R 2 or R 3 is intended to mean a substituent R′ 1 , R′ 2 or R′ 3 that can be converted to R 1 , R 2 and R 3 by one or more chemical reactions.
  • group Z is intended to mean a leaving group or a functional acid derivative, such as an acid chloride, a mixed anhydride or a symmetrical anhydride, or else the acid opportunistically activated, for example, with benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate(BOP), O-benzotriazol-1-yl-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HBTU) or O-benzotriazol-1-yl-N,N,N′,N′-tetramethyluronium tetrafluoroborate (TBTU).
  • BOP benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate
  • HBTU O-benzotriazol-1-yl-N,N,N′,N′-tetramethyluronium tetrafluo
  • R′ 1 , R′ 2 and/or R′ 3 represent a group containing an amine or hydroxyl function
  • these functions can be intermediately protected: an amine function can be protected with an alkanoyl, benzyl, tert-butoxycarbonyl (Boc), benzyloxycarbonyl or 9-fluorenylmethoxycarbonyl (Fmoc) group, for example; a hydroxyl function can be protected in the form of an ether or of an ester, for example.
  • the compounds of the invention can be prepared according to various methods described in the present patent application.
  • aminothiazole derivatives of formula (II) can be prepared by known methods such as those described in documents EP 518 731, EP 611 766 and WO 99/15525.
  • R′ 1 and R′ 2 have the values indicated above, i.e. R′ 1 and R′ 2 represent, respectively, R 1 and R 2 as defined for the compound of general formula (I) or groups that are precursors of R 1 and R 2 ;
  • Hal represents a halogen atom, preferably bromine, chlorine or iodine.
  • the compounds of type (II) with Y ⁇ H, R′ 1 and R′ 2 having the values indicated above can be converted into compounds of type (II) with Y ⁇ F and R′ 1 and R′ 2 having the values indicated above, by reaction with a fluorination agent, for example Selectfluor ⁇ , in a solvent such as DMF or DCM at a temperature ranging from 0° C. to 50° C.
  • a fluorination agent for example Selectfluor ⁇
  • the halogenated ketones of formula 1 can be prepared by processes known to those skilled in the art.
  • the bromoketones can be obtained by reacting bromine, cupric bromide or phenyltrimethylammoniumtribromide (PTT) with an acetophenone derivative of formula:
  • R′ 1 and R′ 2 have the values indicated above, in an organic solvent such as ethyl acetate, a chlorinated solvent or a mixture thereof, or else an alcohol.
  • the hydroxyl function corresponds to a group R′ 1 which can be converted, in a subsequent step, to a group —O—W such as —O—(C 1 -C 8 )alkyl, trifluoromethoxy, trifluoroethoxy, allyloxy, (C 3 -C 10 )cycloalkylmethoxy or (C 3 -C 10 ) cycloalkyloxy.
  • a group —O—W such as —O—(C 1 -C 8 )alkyl, trifluoromethoxy, trifluoroethoxy, allyloxy, (C 3 -C 10 )cycloalkylmethoxy or (C 3 -C 10 ) cycloalkyloxy.
  • R′ 1 to R 1 can be carried out either on the aminothiazole of formula (II), or on a compound of formula (I).
  • benzene derivatives substituted with R′ 1 and R′ 2 are commercially available or are prepared by methods known to those skilled in the art.
  • a halobenzene derivative can also be substituted according to the scheme below:
  • a subject of the invention is also the compounds of formula (II.a):
  • the amine derivatives of formula (III) are known or can be prepared according to the methods described in particular in document WO 87/01706 or according to the methods described in the subsequent text.
  • the group A′ represents a group that is a precursor of the group A or a group A as defined above.
  • the procedure may be carried out as follows:
  • the compounds of formula 9 are commercial or can be synthesized from commercial compounds, according to methods known to those skilled in the art.
  • R′ 3 is a precursor group of R 3 , with R 3 representing a group —(CH 2 ) p -A, in which A represents:
  • R 4 , R 5 and R 6 being as defined above, can be prepared by reaction of the compound 10 with A′H in the presence of a base such as K 2 CO 3 , triethylamine or caesium carbonate in a solvent such as THF, acetonitrile, toluene or DMF, at temperatures ranging from 0° C. to 150° C., so as to obtain the compound 11.
  • the compound 11 can then be converted to a compound of formula 9 by reduction of the amide function, for example with LiAlH 4 , diisobutylaluminium hydride (Dibal), BH 3 in THF, ether or toluene, at a temperature of between 0° C. and 70° C., so as to give the compound of formula 9 in which R 3 represents —(CH 2 ) p -A:
  • the compound of formula 10 can be prepared by reaction of a monoprotected piperazine or homopiperazine with a reactant of formula 12 below:
  • Z represents a leaving group or a group derived from the activation of a carboxylic acid function and X represents a leaving group
  • a solvent such as THF, acetonitrile, DMF, or dichloromethane in the presence of a base such as K 2 CO 3 or triethylamine and, when Z represents an —OH group, of a reactant that activates the acid function, such as BOP, TBTU or CDI, according to the scheme below:
  • R′ 3 is a precursor group of R 3 , with R 3 representing a —(CH 2 ) p -A in which A represents:
  • R 7 being as defined above, can be prepared by reaction of the compound 13 with a monoprotected piperazine or homopiperazine in a solvent such as THF, acetonitrile, DMF or dichloromethane in the presence of a base such as K 2 CO 3 or triethylamine and, when Z represents an —OH group, of a reactant that activates the acid function, such as BOP, TBTU or CDI, according to the scheme below:
  • the compound 11 obtained can then be converted to a compound of formula 9 according to the scheme described above.
  • the compound 13 when it is not commercially available, can be obtained by homologation of the commercial carboxylic acid according to conventional methods such as reactions of Arndt-Eistert type (Tetrahedron Lett., 1979, 29, 2667; “Advances in Organic Chemistry”, J. March, 3rd Edition, Wiley Interscience, p. 1405-1407), according to the scheme below:
  • R′ 3 represents a group that is a precursor of the group R 3 , with R 3 representing —(CH 2 ) p CO-A as defined above
  • R 3 representing —(CH 2 ) p CO-A as defined above
  • Z is as defined above
  • a base such as K 2 CO 3 , triethylamine or caesium carbonate
  • Z represents an —OH group
  • a reactant that activates the acid function such as BOP, TBTU or CDI
  • a solvent such as, for example, THF, acetonitrile or DMF
  • the compound 16 is then converted by reduction of the amide function with, for example, LiAlH 4 in THF or ethyl ether at a temperature of between 0 and 50° C.
  • the intermediate obtained is deprotected and then oxidized to the carboxylic acid 17, for example with CrO 3 or with other reactants according to the methods described in “Advances in Organic Chemistry”, J. March, 3rd Edition, Wiley Interscience, p. 1537-1539, according to the scheme below:
  • the compound 17 is then optionally converted so as to give a compound of formula 14, or is used in its acid form (Z ⁇ OH).
  • the compounds of formula 17 can be prepared by reaction of monoprotected piperazine or homopiperazine with a reactant 18 of formula:
  • X is as defined above and R represents a (C 1 -C 4 )alkyl group
  • R represents a (C 1 -C 4 )alkyl group
  • a base such as K 2 CO 3 , triethylamine or caesium carbonate in a solvent such as THF, acetonitrile, toluene or DMF, at temperatures ranging from 25 to 150° C., according to the scheme below:
  • the compound 19 obtained is then converted to the acid of formula 17 by saponification or acid hydrolysis or any other method known to those skilled in the art.
  • R′ 3 represents a group that is a precursor of the group R 3 , with R 3 representing a group —CO(CH 2 ) p -A, in which A represents:
  • R′ 3 represents a group that is a precursor of the group R 3 , with R 3 representing a group —CO(CH 2 ) p -A, in which A represents:
  • R′ 3 represents a group that is a precursor of the group R 3 , with R 3 representing a group —B
  • R 3 representing a group —B
  • a reducing agent such as NaHB(OAc) 3 , NaBH 3 CN in a solvent such as 1,2-dichloroethane, dichloromethane or THF at temperatures ranging from 0° C. to 70° C.
  • ketones B′ used are commercial or can be synthesized according to the method described in J. Org. Chem., 1989, 54, 1249-1256.
  • the compounds of the invention are obtained by coupling the aminothiazole derivative of formula (II) in which R 1 , R 2 and Y are as defined above, with an amine derivative of formula (III) in which R′ 3 represents a precursor group of R 3 or a group R 3 as defined above, and a is as defined above.
  • the aminothiazole derivative of formula (II) is placed in the presence of a coupling agent for a period of 2 to 16 hours, and then with the amine derivative of formula (III) for a period of 0.5 to 4 hours.
  • the coupling agent can be chosen from those that are known to those skilled in the art, for example phosgene, di-(N-succinimidyl)carbonate or 1,1′-carbonyldiimidazole, according to the methods described in “Encyclopedia of Reagents for Organic Synthesis”, L. A. Paquette, volume 2, p. 1006; volume 4, p. 2304; volume 6, p. 4107.
  • the reaction can be carried out in various solvents, for example dichloromethane, dimethylformamide or toluene, in the presence of a base such as triethylamine or K 2 CO 3 , at a temperature ranging from 0° C. to 100° C.
  • a base such as triethylamine or K 2 CO 3
  • R 3 represents a group —CO(CH 2 ) p -A (or —CO(CH 2 ) p -A′) in which A and p are as defined above and A′ represents a precursor group of A, can also be prepared according to scheme below.
  • reaction is carried out in a solvent such as tetrahydrofuran or dimethylformamide in the presence of a base such as triethylamine or K 2 CO 3 , at temperatures ranging from ambient temperature to 150° C., for a period of 1 to 24 hours.
  • a solvent such as tetrahydrofuran or dimethylformamide
  • a base such as triethylamine or K 2 CO 3
  • the compounds of formula (I) can be prepared from the compound of formula (XII) in which the group A is protected prior to the reducing reaction, in particular when the group A contains functions that are incompatible with the type of reducing agent used. After reduction, a compound of formula (I) is then obtained by deprotection of the group A and optional functionalization of the group A.
  • the compound of formula (V) is then deprotected, according to the methods known to those skilled in the art, to give the compound of formula (VI), which is reacted with the compound of formula (VII) in which Z represents a leaving group or a group derived from the activation of a carboxylic acid function and X represents a leaving group, to give the compound of formula (VIII) in which R 1 , R 2 , Y, X and a are as defined above.
  • the compound of formula (VII) in which X is as defined above and Z represents a leaving group or a group derived from the activation of a carboxylic acid function can be coupled to the compound of formula (IV) by acylation or peptide-type coupling in the presence of a base such as K 2 CO 3 , triethylamine or caesium carbonate or of a coupling reactant such as BOP, TBTU or CDI, in a solvent such as, for example, THF, acetonitrile or DMF, at temperatures ranging from 0° C. to 150° C.
  • a base such as K 2 CO 3 , triethylamine or caesium carbonate or of a coupling reactant such as BOP, TBTU or CDI
  • a solvent such as, for example, THF, acetonitrile or DMF
  • R 1 and R 2 are in the 2-position and 5-position, respectively, with respect to the phenyl.
  • the solid is suspended in a water/dichloromethane mixture and a return to the base is achieved by adding sodium hydroxide.
  • the aqueous phase is extracted twice in dichloromethane.
  • the combined organic phases are dried over MgSO 4 and then evaporated.
  • the oil obtained is chromatographed on silica gel, to give 12 g of the expected product in the form of a powder.
  • the solid is suspended in a water/dichloromethane mixture and a return to the base is achieved by adding sodium hydroxide.
  • the aqueous phase is extracted twice in dichloromethane.
  • the combined organic phases are dried over MgSO 4 and then evaporated, to give 0.34 g of a yellow oil that crystallizes slowly.
  • the mother liquors are evaporated and then stirred in a water/dichloromethane mixture and a return to the base is achieved by adding sodium hydroxide.
  • the aqueous phase is extracted twice in dichloromethane.
  • the combined organic phases are dried over MgSO 4 and then evaporated.
  • the oil obtained is chromatographed on silica gel, to give 0.18 g of the expected compound.
  • the medium is then deoxygenated with nitrogen, and 332 mg of palladium benzyl(chloro)bis(triphenylphosphine) in 5 ml of anhydrous THF are introduced.
  • the medium is stirred at 0° C. for 2 h 30 min and then at AT for 72 hours.
  • the medium is run into a 2.5M HCl solution and then extracted in ether.
  • the organic phase is washed with NaHCO 3 at 5% in water, with water, and then with a saturated NaCl solution. After drying over MgSO 4 and evaporation, the crude is purified by flash chromatography on silica, to give 2.25 g of a white solid.
  • the solid is suspended in a water/dichloromethane mixture and a return to the base is achieved by adding sodium hydroxide.
  • the aqueous phase is extracted twice in dichloromethane.
  • the combined organic phases are dried over MgSO 4 and then evaporated, to give 1.63 g of a yellow solid.
  • a suspension of 5.6 g of AlCl 3 in 40 ml of dichloromethane is cooled to ⁇ 10° C. 3 ml of AcCl and 4 g of the compound of the previous step are added.
  • the medium is stirred for 1 hour at ⁇ 10° C., and then poured into a beaker containing ice mixed with 35% HCl. After separation by settling out, the combined organic phases are dried over MgSO 4 and then evaporated, to give 4.54 g of the expected product.
  • a suspension of 10.6 g of AlCl 3 in 150 ml of dichloromethane is cooled to ⁇ 10° C. 5.7 ml of AcCl and 6 g of 4-propylanisole are added.
  • the medium is stirred at ⁇ 10° C. for 30 min, and then poured into a beaker containing ice mixed with 35% HCl. After separation by settling out, the aqueous phase is extracted 3 times in dichloromethane, and the combined organic phases are washed with water and with a saturated NaCl solution, dried over MgSO 4 and then evaporated, to give 7.86 g of a brown oil (quant.).
  • the mother liquors are evaporated and then stirred in a water/dichloromethane mixture and a return to the base is achieved by adding sodium hydroxide.
  • the aqueous phase is extracted twice in dichloromethane.
  • the combined organic phases are dried over MgSO 4 and then evaporated.
  • the oil obtained is chromatographed on silica gel, to give 580 mg of the expected product.
  • Y represents a fluorine atom (preparations 1.26 and 1.27),
  • R 1 and R 2 are in the 2-position and 5-position, respectively, with respect to the phenyl.
  • 600 mg of the expected product are obtained in the form of a white powder.
  • the compound is prepared according to preparation 1.26, from the compound of preparation 1.4.
  • R 1 2-OMe
  • R 2 5-nPr
  • R 1 2-OCH 3 ;
  • R 2 5-(CH 2 ) 2 CH 3 ;
  • R 1 2-OCH 3 ;
  • R 2 5-(CH 2 ) 2 CH 3 ;
  • R 1 2-OCH 3 ;
  • R 2 5-CyHex;
  • step 3.1 The crude obtained in step 3.1 is dissolved in 75 ml of toluene. 12.16 g of benzylpiperazine are added, and the reaction medium is sealed and then heated at 150° C. for 5 hours. After a return to AT, the medium is diluted in an ether/pentane mixture (1/1), and washed twice with a saturated NaHCO 3 solution, twice in water, and then with a saturated NaCl solution. After drying over MgSO 4 and evaporation, the crude is purified by flash chromatography on silica gel, to give 5.73 g of the expected solid.
  • R 1 2-OCH 3 ;
  • R 2 5-CyHex;
  • R 1 2-OCH 3 ;
  • R 2 5-CyHex;
  • R 3 4-(piperidin-3-yl);
  • the medium is returned to AT and is then refluxed for 45 min.
  • the medium is evaporated and then taken up in 10 ml of MeOH and refluxed for 1 h.
  • the crude is filtered, and the solid is rinsed with ether and dried, to give 1.27 g of the expected compound in the form of a trihydrochloride.
  • R 1 2-OCH 3 ;
  • R 2 5-CyHex;
  • 0.05 ml of acetone followed by 0.15 g of NaBH(OAc) 3 are added to a solution of 0.2 g of the compound obtained in step 4.4, in 1.2 ml of DCE, and the medium is stirred at AT for 3 h.
  • 0.1 ml of Et 3 N and then 0.1 mg of NaBH(OAc) 3 are added.
  • the medium is stirred at AT for 12 h.
  • the medium is concentrated and then taken up in EtOAc.
  • the organic phase is washed twice with a saturated NaHCO 3 solution, and then with a saturated NaCl solution. After drying over MgSO 4 , the organic phase is concentrated and then purified by flash chromatography to give 0.11 g of the expected product.
  • R 1 2-OCH 3 ;
  • R 2 5-CyHex;
  • R 1 2-OCH 3 ;
  • R 2 5-CyHex;
  • 162 ml of a molar solution of borane in THF are added, at 0° C., to a solution of 14 g of the compound prepared in step 5.1, in 50 ml of THF, over a period of 30 min.
  • the medium is stirred at AT for 24 hours and then hydrolysed by the addition of water at 0° C. After dilution in EtOAc, the medium is washed three times with a saturated Na 2 CO 3 solution, and then with a saturated NaCl solution. After drying over MgSO 4 and evaporation, 12.6 g of the expected compound are recovered.
  • the compounds according to the invention were subjected to pharmacological assays in order to determine their modulatory effect on the activity of chemokine receptors.
  • Chemokines are low molecular weight proteins that belong to the pro-inflammatory cytokine family and are involved in leukocyte and endothelial cell chemotaxis. Chemokines control many biological processes and are associated with inflammatory disorders that appear during states of stress, during injuries or during infections; modulating the effect of chemokines makes it possible to prevent or treat pathologies such as asthma, arthritis, allergies, autoimmune diseases, atherosclerosis or angiogenesis (C. D. Paavola et al., J. Biol. Chem., 1998, 273, (50), 33157-33165).
  • pathologies such as asthma, arthritis, allergies, autoimmune diseases, atherosclerosis or angiogenesis
  • hMCP-1 human monocyte chemotactic protein which belongs to the CC chemokine group and which is a natural agonist of the CCR2b receptor, is distinguished.
  • the inhibitory activity of the compounds according to the invention on cells expressing the human CCR2b receptor was measured.
  • the concentration of natural agonist hMCP-1 that inhibits 50% (IC 50 ) of the activity of the CCR2b receptor is 0.57 nM.
  • the compounds according to the invention exhibit an IC 50 that is generally less than 0.1 ⁇ M.
  • Compound No. 14 exhibited an IC 50 of 0.0033 ⁇ M
  • Compound No. 55 exhibited an IC 50 of 0.014 ⁇ M.
  • hMCP-1 exhibits an IC 50 of 6 nM.
  • the compounds according to the invention exhibit an IC 50 that is generally less than 1 ⁇ M.
  • the inhibition of chemotaxis by the compounds according to the invention is a sign of their antagonistic activity on chemokine receptors, and in particular the CCR2b receptor.
  • the inhibitory activity of the compounds according to the invention was also measured on PBMCs (peripheral blood mononuclear cells) infected with the HIV-1 Bal virus, according to a technique adapted from that described by V. Dolle et al., J. Med. Chem., 2000, 43, 3949, 3962. According to this technique, the PBMCs are infected with HIV-1 Bal and the compounds to be tested are then added to the culture medium for 5 days. At the end of this exposure, the amount of reverse transcriptase in the supernatant is measured, which correlates with the level of viral replication in the cells.
  • AZT a reference molecule which inhibits viral replication
  • AZT a reference molecule which inhibits viral replication
  • Compounds according to the invention also exhibit IC 50 values of less than 1 ⁇ M.
  • Compound No. 30 showed an IC 50 of 0.6 ⁇ M.
  • the compounds according to the invention can therefore be used for preparing medicinal products, in particular medicinal products that are agonists of the effect of chemokines.
  • a subject of the present invention is medicinal products which comprise a compound of formula (I) or an addition salt of the latter with a pharmaceutically acceptable acid, or else a hydrate or a solvate.
  • the present invention relates to pharmaceutical compositions comprising, as active principle, a compound according to the invention.
  • These pharmaceutical compositions contain an effective dose of at least one compound according to the invention, or a pharmaceutically acceptable salt, or a hydrate or solvate of said compound, and also at least one pharmaceutically acceptable excipient.
  • Said excipients are chosen, according to the pharmaceutical form and the method of administration desired, from the usual excipients that are known to those skilled in the art.
  • compositions of the present invention for oral, sublingual, subcutaneous, intamuscular, intravenous, topical, local, intratracheal, intranasal, transdermal or rectal administration the active principle of formula (I) above, or its possible salt, solvate or hydrate, can be administered in unit administration form, as a mixture with conventional pharmaceutical excipients, to animals and to human beings for the prophylaxis or the treatment of the disorders or of the diseases above.
  • the suitable unit administration forms comprise oral forms such as tablets, soft or hard gelatin capsules, powders, granules and oral solutions or suspensions, sublingual, buccal, intratracheal, intraocular and intranasal administration forms, forms for administration by inhalation, topical, transdermal, subcutaneous, intramuscular or intravenous administration forms, rectal administration forms, and implants.
  • oral forms such as tablets, soft or hard gelatin capsules, powders, granules and oral solutions or suspensions
  • sublingual, buccal, intratracheal intraocular and intranasal administration forms, forms for administration by inhalation
  • topical, transdermal, subcutaneous, intramuscular or intravenous administration forms rectal administration forms, and implants.
  • the compounds according to the invention can be used in creams, gels, ointments or lotions.
  • a unit administration form of a compound according to the invention in the form of a tablet can comprise the following constituents:
  • the dose of active principle administered per day can reach 0.1 to 1000 mg/kg, taken in one or more doses.
  • the dosage appropriate for each patient is determined by the physician according to the method of administration, and the weight and response of said patient.
  • the present invention also relates to a method of treating the pathologies indicated above, which comprises the administration of an effective dose of a compound according to the invention, or one of its pharmaceutically acceptable salts or hydrates or solvates, to a patient.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The disclosure concerns 2-carbamide-4-phenylthiazole derivatives of general formula (I). The disclosure also concerns pharmaceutical compositions containing a compound of general formula (I) and to processes for preparing and methods of using compounds of general formula (I).
Figure US07767681-20100803-C00001

Description

The invention relates to 2-carbamide-4-phenylthiazole derivatives, to the preparation thereof and to the therapeutic use thereof.
A subject of the invention is compounds corresponding to formula (I) below:
Figure US07767681-20100803-C00002
in which
    • (i) R1 is selected from the group consisting of H, halogen, (C1-C8)alkyl, trifluoro(C1-C4)alkyl, —OH, —O—(C1-C8)alkyl, —O-trifluoro (C1-C8)alkyl, —O—(C3-C10)cycloalkyl(C1-C8)alkyl, —O—(C3-C10)cycloalkyl, —O—CH2—CH═CH2 and (C1-C4)alkylthio;
    • (ii) R2 is selected from the group consisting of H, halogen, —OH, (C1-C8)alkyl, trifluoro(C1-C4)alkyl, perfluoro(C1-C4)alkyl, (C3-C10)cycloalkyl, —O—(C1-C8)alkyl, —O—(C3-C10)cycloalkyl(C1-C8)alkyl, —O—(C3-C10)cycloalkyl, —O—CH2—CH═CH2 and (C3-C8)cycloalkyl(C1-C8)alkyl;
    • (iii) Y represents a hydrogen atom or a halogen;
    • (iv) R3 represents:
      a1) a group of formula —(CH2)p-A
      in which p represents 0, 1, 2, 3 or 4, and:
    • when p represents 2, 3 or 4, A represents a group of formula:
Figure US07767681-20100803-C00003
—NR4R5,
in which R6 is selected from the group consisting of H, F, (C1-C4)alkyl, —(CH2)nOH, —(CH2)nO(C1-C4)alkyl and —(CH2)nNR4R5, where n represents 0, 1 or 2, and R4 and R5 represent, independently of one another, a hydrogen atom, or a (C1-C8)alkyl, —CO(C1-C4)alkyl or —CO—O—(C1-C8)alkyl group;
    • or, when p represents 1, 2, 3 or 4, A represents a group of formula:
Figure US07767681-20100803-C00004
in which R7 is selected from the group consisting of H, (C1-C8)alkyl, —CO—(C1-C8)alkyl, benzyl, —CO—O—(C1-C8)alkyl, —CO—O-benzyl, —CO-phenyl, —CO-heteroaryl, —CO—(C3-C10)cycloalkyl, —SO2—(C1-C8)alkyl, —SO2—(C3-C8)cycloalkyl and —SO2-heteroaryl;
    • or, when p represents 0, 1, 2, 3 or 4, A represents a group of formula:
Figure US07767681-20100803-C00005
said group being optionally substituted with a (C1-C4)alkyl group;
a2) a group of formula —(CH2)p—CO-A
in which p represents 1, 2, 3 or 4,
    • A represents a group of formula:
Figure US07767681-20100803-C00006
—NR4R5,
in which R4, R5 and R6 are as defined above;
a3) a group of formula —CO(CH2)p-A
in which p represents 0, 1, 2, 3 or 4
    • when p represents 1, 2, 3 or 4, A represents a group of formula:
Figure US07767681-20100803-C00007
—NR4R5,
in which R4, R5 and R6 are as defined above;
    • or, when p represents 0, 1, 2, 3 or 4, A represents a group of formula:
Figure US07767681-20100803-C00008
in which R7 is as defined above;
    • or, when p represents 0, 1, 2, 3 or 4, A represents a group of formula:
Figure US07767681-20100803-C00009
said group being optionally substituted with a (C1-C4)alkyl group;
a4) a group —B
in which B represents a group of formula:
Figure US07767681-20100803-C00010
in which R7 is as defined above;
    • (v) a represents 2 or 3.
A preferred halogen is a fluorine.
The compounds of formula (I) may contain one or more asymmetric carbon atoms. They may therefore exist in the form of enantiomers or of diastereoisomers. These enantiomers and diastereoisomers, and also mixtures thereof, including racemic mixtures, form part of the invention.
The compounds of formula (I) may exist in the form of bases or of addition salts with acids. Such addition salts form part of the invention.
These salts are advantageously prepared with pharmaceutically acceptable acids, but the salts of other acids that are useful, for example, for purifying or isolating the compounds of formula (I) also form part of the invention.
The compounds of formula (I) may also exist in the form of hydrates or of solvates, i.e. in the form of associations or combinations with one or more water molecules or with a solvent. Such hydrates and solvates also form part of the invention.
In the context of the present invention:
    • the term “Ct-z” where t and z may have the values of 1 to 10, is intended to mean a carbon chain that may have from t to z carbon atoms, for example the term “C1-3” is intended to mean a carbon chain that may have from 1 to 3 carbon atoms;
    • the term “Hal” is intended to mean a halogen atom such as a fluorine, a chlorine, a bromine or an iodine;
    • the term “an alkyl group” is intended to mean a saturated, linear or branched aliphatic group optionally substituted with a halogen atom. By way of examples, mention may be made of methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, 2-fluoroethyl groups, etc.;
    • the term “a cycloalkyl group” is intended to mean a cyclic alkyl group. By way of examples, mention may be made of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl groups, etc.;
    • the term “an alkoxy group” is intended to mean an —O-alkyl radical in which the alkyl group is as defined above;
    • the term “a heteroaryl group” is intended to mean an aryl group carrying one or more hetero atoms, optionally substituted with another hetero atom. By way of examples, mention may be made of pyrazine, pyrimidine, pyridazine, pyridine, triazine, triazole, thiazole, oxazole, pyrazole, imidazole, oxopyridine groups, etc.;
    • the term “a perfluoroalkyl group” is intended to mean an alkyl radical, as defined above, for which all the carbon atoms are substituted with fluorine atoms.
Among the compounds which are subjects of the invention, mention may be made of a first group of compounds of formula (I.a) below:
Figure US07767681-20100803-C00011
in which R1, R2, R3 and Y are as defined above.
Compounds of the invention of formula (I.a) are those in which R1 is in the 2-position and R2 is in the 5-position with respect to the phenyl.
Among the compounds which are subjects of the invention, mention may be made of a second group of compounds of formula (I.b) below:
Figure US07767681-20100803-C00012
in which R1, R2, Y, p and A are as defined above.
Compounds of the invention of formula (I.b) are those in which R1 is in the 2-position and R2 is in the 5-position with respect to the phenyl.
Among the compounds which are subjects of the invention, mention may be made of a third group of compounds of formula (I.c) below:
Figure US07767681-20100803-C00013
in which R1, R2, Y and B are as defined above.
Compounds of the invention of formula (I.c) are those in which R1 is in the 2-position and R2 is in the 5-position with respect to the phenyl.
Other compounds of the invention are those for which:
    • R1 represents a —O—(C1-C8)alkyl group and/or;
    • R2 represents a (C1-C8)alkyl, (C3-C10)cycloalkyl, perfluoro(C1-C4)alkyl or —O—(C1-C8)alkyl group.
Among the compounds of formula (I) of the invention, mention should in particular be made of the following compounds:
  • (R)—N-[4-(5-cyclohexyl-2-methoxyphenyl)thiazol-2-yl]-N′-[4-(1-methylpiperidin-3-ylmethyl)piperazin-1-yl]urea (Compound No. 76),
  • N-[4-(2-methoxy-5-propoxyphenyl)thiazol-2-yl]-N′-[4-(2-morpholin-4-ylethyl)piperazin-1-yl]urea (Compound No. 1),
  • N-[4-(2-methoxy-5-propylphenyl)thiazol-2-yl]-N′-[4-(3-piperidin-1-ylpropyl)piperazin-1-yl]urea (Compound No. 11),
  • N-[4-(2-methoxy-5-propylphenyl)thiazol-2-yl]-N′-[4-(2-dimethylaminoethyl)piperazin-1-yl]urea (Compound No. 16),
  • N-[4-(2-methoxy-5-propylphenyl)thiazol-2-yl]-N′-[4-(2-oxo-2-pyrrolidin-1-ylethyl)piperazin-1-yl]urea (Compound No. 20),
  • N-[4-(2-methoxy-5-propylphenyl)thiazol-2-yl]-N′-[4-(2-thiophen-2-ylethyl)piperazin-1-yl]urea (Compound No. 21),
  • N-[4-(2-methoxy-5-propylphenyl)thiazol-2-yl]-N′-[4-[2-(tetrahydrofuran-2-yl)ethyl]piperazin-1-yl]urea (Compound No. 22),
  • N-[4-(2-methoxy-5-propylphenyl)thiazol-2-yl]-N′-[4-(2-pyrrolidin-1-ylacetyl)piperazin-1-yl]urea (Compound No. 31),
  • N-[4-(2-methoxy-5-propylphenyl)thiazol-2-yl]-N′-[4-[2-(3-ethylaminopyrrolidin-1-yl)ethyl]piperazin-1-yl]urea (Compound No. 33),
  • N-[4-(5-cyclohexyl-2-methoxyphenyl)thiazol-2-yl]-N′-[4-(1-methylpiperidin-4-yl)piperazin-1-yl]urea (Compound No. 47),
  • N-[4-(5-cyclohexyl-2-methoxyphenyl)thiazol-2-yl]-N′-[4-(1-benzylpiperidin-3-yl)piperazin-1-yl]urea (Compound No. 68),
  • N-[4-(2-methoxy-5-propylphenyl)thiazol-2-yl]-N′-[4-(2-pyridin-4-ylethyl)piperazin-1-yl]urea (Compound No. 28),
  • N-[4-(2-methoxy-5-pentafluoroethylphenyl)thiazol-2-yl]-N′-[4-(2-pyrrolidin-1-ylethyl)piperazin-1-yl]urea (Compound No. 29),
  • N-[4-(5-cyclohexyl-2-methoxyphenyl)thiazol-2-yl]-N′-[4-(1-isopropylpiperidin-3-yl)piperazin-1-yl]urea (Compound No. 70),
  • N-[4-(5-cyclohexyl-2-methoxyphenyl)thiazol-2-yl]-N′-[4-(2-pyrrolidin-1-ylethyl)piperazin-1-yl]urea (Compound No. 30),
  • N-[4-(5-cyclohexyl-2-methoxyphenyl)-5-fluorothiazol-2-yl]-N′-[4-(1-methylpiperidin-4-yl)piperazin-1-yl]urea (Compound No. 59),
  • N-[4-(5-cyclohexyl-2-methoxyphenyl)thiazol-2-yl]-N′-[4-(2-oxo-2-pyrrolidin-1-ylethyl)piperazin-1-yl]urea (Compound No. 108),
  • N-[4-(5-cyclohexyl-2-ethoxyphenyl)thiazol-2-yl]-N′-[4-(2-oxo-2-pyrrolidin-1-ylethyl)piperazin-1-yl]urea (Compound No. 109),
  • N-[4-(5-cyclohexyl-2-methoxyphenyl)thiazol-2-yl]-N′-[4-(2-oxo-2-morpholino-4-ylethyl)piperazin-1-yl]urea (Compound No. 116),
  • N-[4-(5-cyclohexyl-2-ethoxyphenyl)thiazol-2-yl]-N′-[4-(2-oxo-2-morpholino-4-ylethyl)piperazin-1-yl]urea (Compound No. 110),
  • (S)N-[4-(5-cyclohexyl-2-methoxyphenyl)thiazol-2-yl]-N′-[4-(1-sulphomethylpiperidin-3-ylmethyl)piperazin-1-yl]urea (Compound No. 112),
  • N-[4-(5-cyclohexyl-2-methoxyphenyl)thiazol-2-yl]-N′-[4-(1-oxo-1-(1-oxopyridin-2-yl)meth-1-ylpiperidin-3-yl-methyl)piperazin-1-yl]urea (Compound No. 113).
Some intermediates that are useful for preparing the compounds of formula (I) may also serve as a final product of formula (I), as will emerge in the examples given hereinafter.
Similarly, some compounds of formula (I) of the invention may serve as intermediates that are useful for preparing compounds of formula (I) according to the invention.
In the subsequent text, the expression “protective group Gp” is intended to mean a group that makes it possible, firstly, to protect a reactive function such as a hydroxyl or an amine during a synthesis and, secondly, to regenerate the intact reactive function at the end of synthesis. Examples of protective groups and also methods of protection and of deprotection are given in “Protective Groups in Organic Synthesis”, Green et al., 2nd edition (John Wiley & Sons, Inc., New York).
In the subsequent text, the term “leaving group X” is intended to mean a group that can be readily cleaved from a molecule by breaking a heterolytic bond, with a pair of electrons leaving. This group can thus be readily replaced with another group in a substitution reaction, for example. Such leaving groups are, for example, halogens or an activated hydroxyl group such as a mesyl, tosyl, triflate, acetyl, etc. Examples of leaving groups and also references for the preparation thereof are given in “Advances in Organic Chemistry”, J. March, 3rd Edition, Wiley Interscience, p. 310-316.
In the subsequent text, the expression “precursor of R1, R2 or R3” is intended to mean a substituent R′1, R′2 or R′3 that can be converted to R1, R2 and R3 by one or more chemical reactions.
In the subsequent text, the term “group Z” is intended to mean a leaving group or a functional acid derivative, such as an acid chloride, a mixed anhydride or a symmetrical anhydride, or else the acid opportunistically activated, for example, with benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate(BOP), O-benzotriazol-1-yl-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HBTU) or O-benzotriazol-1-yl-N,N,N′,N′-tetramethyluronium tetrafluoroborate (TBTU).
When one or more substituents R′1, R′2 and/or R′3 represent a group containing an amine or hydroxyl function, these functions can be intermediately protected: an amine function can be protected with an alkanoyl, benzyl, tert-butoxycarbonyl (Boc), benzyloxycarbonyl or 9-fluorenylmethoxycarbonyl (Fmoc) group, for example; a hydroxyl function can be protected in the form of an ether or of an ester, for example.
The compounds of the invention can be prepared according to various methods described in the present patent application.
Before tackling these methods, the methods for preparing the aminothiazole derivatives of formula (II) and the methods for preparing the amine derivatives of formula (III), which are useful for preparing the compounds of formula (I) of the invention, are described below.
The aminothiazole derivatives of formula (II) can be prepared by known methods such as those described in documents EP 518 731, EP 611 766 and WO 99/15525.
In general, when Y═H, thiourea is reacted with a halogenated ketone of formula 1 according to the following reaction scheme:
Figure US07767681-20100803-C00014
The substituents R′1 and R′2 have the values indicated above, i.e. R′1 and R′2 represent, respectively, R1 and R2 as defined for the compound of general formula (I) or groups that are precursors of R1 and R2; Hal represents a halogen atom, preferably bromine, chlorine or iodine.
As indicated on the above scheme, the compounds of type (II) with Y═H, R′1 and R′2 having the values indicated above, can be converted into compounds of type (II) with Y═F and R′1 and R′2 having the values indicated above, by reaction with a fluorination agent, for example Selectfluor©, in a solvent such as DMF or DCM at a temperature ranging from 0° C. to 50° C.
The halogenated ketones of formula 1 can be prepared by processes known to those skilled in the art. For example, the bromoketones can be obtained by reacting bromine, cupric bromide or phenyltrimethylammoniumtribromide (PTT) with an acetophenone derivative of formula:
Figure US07767681-20100803-C00015
in which R′1 and R′2 have the values indicated above, in an organic solvent such as ethyl acetate, a chlorinated solvent or a mixture thereof, or else an alcohol.
When the acetophenone derivative of formula 2 is not commercially available, it can be prepared by various methods:
    • a Friedel-Crafts reaction with benzene substituted with R′1 and R′2, which is reacted with acetyl chloride or acetic anhydride, in the presence of a Lewis acid such as AlCl3 or TiCl4, for example;
    • the action of acetyl chloride, in the presence of palladium, with benzene substituted with R′1 and R′2, after deprotonation of the benzene, for example by the action of butyllithium and then addition of zinc chloride or of manganese iodide. This procedure can be used to prepare an acetophenone derivative of formula 2 in which R′2═R2═(C1-C4)perfluoroalkyl;
    • a Fries rearrangement: from an acetoxybenzene derivative of formula:
Figure US07767681-20100803-C00016
by the action of a Lewis acid, a hydroxyacetophenone derivative is obtained, of formula:
Figure US07767681-20100803-C00017
The hydroxyl function corresponds to a group R′1 which can be converted, in a subsequent step, to a group —O—W such as —O—(C1-C8)alkyl, trifluoromethoxy, trifluoroethoxy, allyloxy, (C3-C10)cycloalkylmethoxy or (C3-C10) cycloalkyloxy.
The conversion of R′1 to R1 can be carried out either on the aminothiazole of formula (II), or on a compound of formula (I).
The benzene derivatives substituted with R′1 and R′2 are commercially available or are prepared by methods known to those skilled in the art.
For example, to prepare a compound in which R1 is a group —O—W as defined above, the following procedure is carried out:
Figure US07767681-20100803-C00018
A halobenzene derivative can also be substituted according to the scheme below:
Figure US07767681-20100803-C00019
In the specific case where R2 represents a (c1-c4)perfluoroalkyl, the procedure can also be carried out according to the reaction scheme below:
Figure US07767681-20100803-C00020
A subject of the invention is also the compounds of formula (II.a):
Figure US07767681-20100803-C00021
in which:
    • R1 represents a halogen atom, or an —O—(C1-C8)alkyl or (C3-C10)cycloalkyl(C1-C8)alkoxy group;
    • R2 represents a (C1-C8)alkoxy, (C1-C8)alkyl, (C3-C10)cycloalkyl, trifluoro(C1-C4)alkyl or perfluoro(c1-c4)alkyl group.
Examples of preparation of aminothiazole derivatives of formula (II) are given in the subsequent text.
The amine derivatives of formula (III) are known or can be prepared according to the methods described in particular in document WO 87/01706 or according to the methods described in the subsequent text.
In the subsequent text, the group A′ represents a group that is a precursor of the group A or a group A as defined above.
The compounds of formula (III) in which R′3 represents a precursor group of R3 or a group R3 as defined above, and in which a is as defined above, are obtained from compounds of formula 9 by deprotection of the nitrogen of the piperazine or of the homopiperazine, protected according to methods known to those skilled in the art or described in the literature (WO 03/104230 and WO 03/057145).
By way of example, the procedure may be carried out as follows:
Figure US07767681-20100803-C00022
The compounds of formula 9 are commercial or can be synthesized from commercial compounds, according to methods known to those skilled in the art.
Preparation 2.1
The compounds of formula 9 in which R′3 is a precursor group of R3, with R3 representing a group —(CH2)p-A, in which A represents:
Figure US07767681-20100803-C00023
and p is 2, 3 or 4, R4, R5 and R6 being as defined above, can be prepared by reaction of the compound 10 with A′H in the presence of a base such as K2CO3, triethylamine or caesium carbonate in a solvent such as THF, acetonitrile, toluene or DMF, at temperatures ranging from 0° C. to 150° C., so as to obtain the compound 11. The compound 11 can then be converted to a compound of formula 9 by reduction of the amide function, for example with LiAlH4, diisobutylaluminium hydride (Dibal), BH3 in THF, ether or toluene, at a temperature of between 0° C. and 70° C., so as to give the compound of formula 9 in which R3 represents —(CH2)p-A:
Figure US07767681-20100803-C00024
The compound of formula 10 can be prepared by reaction of a monoprotected piperazine or homopiperazine with a reactant of formula 12 below:
Figure US07767681-20100803-C00025
in which Z represents a leaving group or a group derived from the activation of a carboxylic acid function and X represents a leaving group, in a solvent such as THF, acetonitrile, DMF, or dichloromethane in the presence of a base such as K2CO3 or triethylamine and, when Z represents an —OH group, of a reactant that activates the acid function, such as BOP, TBTU or CDI, according to the scheme below:
Figure US07767681-20100803-C00026
Preparation 2.2
The compounds of formula 9 in which R′3 is a precursor group of R3, with R3 representing a —(CH2)p-A in which A represents:
Figure US07767681-20100803-C00027
and p represents 1, 2, 3 or 4, R7 being as defined above, can be prepared by reaction of the compound 13 with a monoprotected piperazine or homopiperazine in a solvent such as THF, acetonitrile, DMF or dichloromethane in the presence of a base such as K2CO3 or triethylamine and, when Z represents an —OH group, of a reactant that activates the acid function, such as BOP, TBTU or CDI, according to the scheme below:
Figure US07767681-20100803-C00028
The compound 11 obtained can then be converted to a compound of formula 9 according to the scheme described above.
The compound 13, when it is not commercially available, can be obtained by homologation of the commercial carboxylic acid according to conventional methods such as reactions of Arndt-Eistert type (Tetrahedron Lett., 1979, 29, 2667; “Advances in Organic Chemistry”, J. March, 3rd Edition, Wiley Interscience, p. 1405-1407), according to the scheme below:
Figure US07767681-20100803-C00029
Preparation 2.3
The compounds of formula 9 in which R′3 represents a group that is a precursor of the group R3, with R3 representing —(CH2)pCO-A as defined above, can be obtained from the compounds of formula 14 in which Z is as defined above, by reaction with A′H in the presence of a base such as K2CO3, triethylamine or caesium carbonate and, when Z represents an —OH group, of a reactant that activates the acid function, such as BOP, TBTU or CDI, in a solvent such as, for example, THF, acetonitrile or DMF, at temperatures ranging from 0° C. to 150° C., according to the scheme below:
Figure US07767681-20100803-C00030
The compounds of formula 14, when they are not commercially available, can be obtained from a monoprotected piperazine or homopiperazine and the reactant 15 in which Z is as defined above, by acylation or peptide-type coupling in the presence of a base such as K2CO3, triethylamine or caesium carbonate or of a coupling reactant such as BOP, TBTU or CDI, in a solvent such as, for example, THF, acetonitrile or DMF, at temperatures ranging from 0° C. to 150° C., according to the scheme below:
Figure US07767681-20100803-C00031
The compound 16 is then converted by reduction of the amide function with, for example, LiAlH4 in THF or ethyl ether at a temperature of between 0 and 50° C. The intermediate obtained is deprotected and then oxidized to the carboxylic acid 17, for example with CrO3 or with other reactants according to the methods described in “Advances in Organic Chemistry”, J. March, 3rd Edition, Wiley Interscience, p. 1537-1539, according to the scheme below:
Figure US07767681-20100803-C00032
The compound 17 is then optionally converted so as to give a compound of formula 14, or is used in its acid form (Z═OH).
Alternatively, the compounds of formula 17 can be prepared by reaction of monoprotected piperazine or homopiperazine with a reactant 18 of formula:
Figure US07767681-20100803-C00033
in which X is as defined above and R represents a (C1-C4)alkyl group, by alkylation of the nitrogen in the presence of a base such as K2CO3, triethylamine or caesium carbonate in a solvent such as THF, acetonitrile, toluene or DMF, at temperatures ranging from 25 to 150° C., according to the scheme below:
Figure US07767681-20100803-C00034
The compound 19 obtained is then converted to the acid of formula 17 by saponification or acid hydrolysis or any other method known to those skilled in the art.
Preparation 2.4
The compounds of formula 9 in which R′3 represents a group that is a precursor of the group R3, with R3 representing a group —CO(CH2)p-A, in which A represents:
Figure US07767681-20100803-C00035
and p representing 1, 2, 3 or 4, and R4, R5 and R6 being as defined above, can be prepared using the method described in preparation 2.1 above.
Preparation 2.5
The compounds of formula 9 in which R′3 represents a group that is a precursor of the group R3, with R3 representing a group —CO(CH2)p-A, in which A represents:
Figure US07767681-20100803-C00036
and p representing 0, 1, 2, 3 or 4, and R7 being as defined above, can be prepared using the method described in preparation 2.1 above.
Preparation 2.6
The compounds of formula 9 in which R′3 represents a group that is a precursor of the group R3, with R3 representing a group —B, can be prepared by reaction of a monoprotected piperazine or homopiperazine and of a ketone B′ that is a precursor of B, by means of a reductive amination reaction in the presence of a reducing agent such as NaHB(OAc)3, NaBH3CN in a solvent such as 1,2-dichloroethane, dichloromethane or THF at temperatures ranging from 0° C. to 70° C. (Synth. Commun., 1998, 28 (10), 1897-1905, J. Org. Chem., 1992, 57 (11), 3218-3225, J. Org. Chem., 1996, 61, 3849-3862, Tetrahedron Lett., 1990, 31, 5595-5598), according to the scheme below:
Figure US07767681-20100803-C00037
The ketones B′ used are commercial or can be synthesized according to the method described in J. Org. Chem., 1989, 54, 1249-1256.
The compounds of formula (I) of the invention can be prepared according to general scheme 1 below:
Figure US07767681-20100803-C00038
According to scheme 1, the compounds of the invention are obtained by coupling the aminothiazole derivative of formula (II) in which R1, R2 and Y are as defined above, with an amine derivative of formula (III) in which R′3 represents a precursor group of R3 or a group R3 as defined above, and a is as defined above.
According to scheme 1, the aminothiazole derivative of formula (II) is placed in the presence of a coupling agent for a period of 2 to 16 hours, and then with the amine derivative of formula (III) for a period of 0.5 to 4 hours.
The coupling agent can be chosen from those that are known to those skilled in the art, for example phosgene, di-(N-succinimidyl)carbonate or 1,1′-carbonyldiimidazole, according to the methods described in “Encyclopedia of Reagents for Organic Synthesis”, L. A. Paquette, volume 2, p. 1006; volume 4, p. 2304; volume 6, p. 4107.
The reaction can be carried out in various solvents, for example dichloromethane, dimethylformamide or toluene, in the presence of a base such as triethylamine or K2CO3, at a temperature ranging from 0° C. to 100° C.
The compounds of the invention of formula (I) in which R3 represents a group —CO(CH2)p-A (or —CO(CH2)p-A′) in which A and p are as defined above and A′ represents a precursor group of A, can also be prepared according to scheme below.
Figure US07767681-20100803-C00039
According to scheme 2, the aminothiazole derivative of formula (VIII) in which R1, R2, Y, a and p are as defined above and X represents a leaving group is reacted with a group A′H that is a precursor of the group A or a group AH as defined above, to give the compound of formula (XII) (compound of formula (I) in which R3 represents a group —CO(CH2)p-A).
The reaction is carried out in a solvent such as tetrahydrofuran or dimethylformamide in the presence of a base such as triethylamine or K2CO3, at temperatures ranging from ambient temperature to 150° C., for a period of 1 to 24 hours.
The compounds of the invention of formula (I) in which R3 represents a group —(CH2)p-A can be prepared in the known manner, from the compound of formula (XII) as defined above, directly by reduction of the carbonyl function with a reducing agent such as Red-Al or LiAlH4 according to scheme 3 below:
Figure US07767681-20100803-C00040
Alternatively, the compounds of formula (I) can be prepared from the compound of formula (XII) in which the group A is protected prior to the reducing reaction, in particular when the group A contains functions that are incompatible with the type of reducing agent used. After reduction, a compound of formula (I) is then obtained by deprotection of the group A and optional functionalization of the group A.
The compounds of formula (VIII) can be prepared according to scheme 4 below:
Figure US07767681-20100803-C00041
According to scheme 4, the aminothiazole derivative of formula (II) as defined above is coupled to an amine derivative of formula (IV) in which Gp represents a protective group, for example a benzyl or Boc group, and a is as defined above, to give the compound of formula (V).
The reaction is carried out under the same conditions as those described above for scheme 1.
The compound of formula (V) is then deprotected, according to the methods known to those skilled in the art, to give the compound of formula (VI), which is reacted with the compound of formula (VII) in which Z represents a leaving group or a group derived from the activation of a carboxylic acid function and X represents a leaving group, to give the compound of formula (VIII) in which R1, R2, Y, X and a are as defined above.
Alternatively, the compounds of formula (VIII) can be prepared according to scheme 5 below.
Figure US07767681-20100803-C00042
According to scheme 5, the compound of formula (VII) in which X is as defined above and Z represents a leaving group or a group derived from the activation of a carboxylic acid function can be coupled to the compound of formula (IV) by acylation or peptide-type coupling in the presence of a base such as K2CO3, triethylamine or caesium carbonate or of a coupling reactant such as BOP, TBTU or CDI, in a solvent such as, for example, THF, acetonitrile or DMF, at temperatures ranging from 0° C. to 150° C. The compound (IX) is thus obtained. The compound (X), obtained by deprotection of the compound (IX), is then coupled with an aminothiazole compound of formula (II) under conditions identical to those of scheme 1.
In the general synthesis schemes, the starting compounds and the reactants, when the method for preparing them is not described, are commercially available or are described in the literature, or else can be prepared according to methods that are described therein or that are known to those skilled in the art.
The examples that follow describe the preparation of compounds in accordance with the invention. These compounds are not limiting and merely illustrate the present invention. The numbers of the compounds exemplified refer to those given in Table II, which illustrates the chemical structures and the physical properties of some compounds according to the invention.
In the preparations and examples that follow:
    • CyHex=a cyclohexyl group;
    • AT=ambient temperature;
    • DCM=dichloromethane
    • DSC=di-(N-succinimidyl)carbonate
    • DIPEA=diisopropylethylamine
    • THF=tetrahydrofuran
    • BOP=benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate
    • Mp=melting point
    • CDI=1,1′-carbonyldiimidazole
    • DMF=dimethylformamide
    • DCE=dichloroethane
    • TFA=trifluoroacetic acid
    • Red-Al®=sodium bis(2-methoxyethoxy)aluminium hydride
    • TBME=tert-butyl methyl ether
    • TBTU=2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate
Preparation of Aminothiazole Derivatives of Formula (II)
Compounds of formula (II) in which:
Y represents —H (preparations 1.1 to 1.25),
R1 and R2 are in the 2-position and 5-position, respectively, with respect to the phenyl.
Preparation 1.1 4-(2-Methoxy-5-propoxyphenyl)-1,3-thiazol-2-amine A) 1-(2-Hydroxy-5-propoxyphenyl)ethanone
10 g of 2,5-dihydroxyacetophenone suspended in 100 ml of acetone are placed in a 500 ml round-bottomed flask, and 9.14 g of anhydrous K2CO3 are added, followed by 12.4 g of propyl iodide. The reaction medium is refluxed for 30 hours. After a return to ambient temperature, the medium is filtered through Celite® and then concentrated. The brown oil obtained is taken up in EtOAc, filtered, and washed with water, with a 2M HCl solution and then with a saturated NaCl solution. The organic phase is evaporated off to give a black paste. The paste is taken up in chloroform and filtered. The medium is concentrated to give 11.4 g of a black solid. The latter is taken up in absolute ethanol. The solution is placed in a freezer for 10 minutes, and a solid precipitates and is collected by filtration. The filtrate is concentrated, taken up in ethanol, cooled in a freezer, and then filtered again. This operation is repeated 4 times to give 8.35 g of the expected compound in the form of a powder.
B) 1-(2-Methoxy-5-propoxyphenyl)ethanone
49.8 g of K2CO3 followed by 22.4 ml of methyl iodide are added to a solution of 35 g of the solid above in 350 ml of DMF. The reaction medium is heated for 12 hours at 60° C. After a return to ambient temperature, the medium is filtered through Celite®, diluted in ether and washed with a 2M HCl solution. The aqueous phase is extracted twice in ether. The combined organic phases are washed with a dilute sodium hydroxide solution, and then washed with water, twice, and with a saturated NaCl solution. The organic phase is dried over MgSO4, and then evaporated to give 35.55 g of a brown oil. The oil is distilled under reduced pressure at 115° C., to give 32.8 g of the expected compound in the form of an oil.
C) 2-Bromo-1-(2-methoxy-5-propoxyphenyl)ethanone
4.8 ml of bromine are added dropwise to a solution of 16.4 g of the oil obtained in the previous step, in 100 ml of methanol. The medium is stirred for 30 minutes at ambient temperature and then evaporated. The oil obtained is taken up in dichloromethane, washed 3 times in water, then dried over MgSO4 and evaporated to give 24.5 g of a brown oil.
D) 4-(2-Methoxy-5-propoxyphenyl)-1,3-thiazol-2-amine
24.5 g of thiourea are added to a solution of 42 g of the bromoketone prepared in the previous step, in 200 ml of ethanol. The medium is refluxed for 1 hour 30 minutes. The medium is then placed in a refrigerator for 12 hours, and then filtered. The solid thus collected is rinsed with a small amount of cold ethanol, and then with ether. 25 g of hydrobromide are recovered.
The solid is suspended in a water/dichloromethane mixture and a return to the base is achieved by adding sodium hydroxide. The aqueous phase is extracted twice in dichloromethane. The combined organic phases are dried over MgSO4 and then evaporated. The oil obtained is chromatographed on silica gel, to give 12 g of the expected product in the form of a powder.
Mp=76° C.
Preparation 1.2 4-(5-Butyl-2-methoxyphenyl)-1,3-thiazol-2-amine A) 4-Butylphenyl acetate
A solution of 10 g of 4-n-butylphenol, 10 ml of Ac2O and 8 ml of pyridine is stirred at reflux in 10 ml of dichloromethane. After 2 hours, the medium is cooled to ambient temperature, diluted in dichloromethane, washed with water, washed with a 1M HCl solution, washed in a saturated CuSO4 solution, washed with water, and dried over MgSO4. After evaporation, 10.8 g of the expected compound are recovered in the form of an oil.
B) 1-(5-Butyl-2-hydroxyphenyl)ethanone
3.22 g of AlCl3 are added, in several portions, to 5 g of the oil obtained in the previous step, in a 100 ml round-bottomed flask. The medium is heated at 130° C. for 1 hour. After a return to ambient temperature, a solution of ice-cold water acidified with 35% HCl is run into the reaction crude. The medium is placed in an ultrasound bath. EtOAc is added so as to obtain solubilization of the medium after 15 minutes. The aqueous phase is extracted 3 times in EtOAc, and the organic phases are washed with water and then with a saturated NaCl solution. After drying over MgSO4 and evaporation, 4.5 g of a yellow oil are recovered.
C) 1-(5-Butyl-2-methoxyphenyl)ethanone
1.44 g of K2CO3 followed by 0.648 ml of methyl iodide are added to a solution of 1 g of the oil obtained in the previous step, in 10 ml of DMF. The medium is heated at 60° C. overnight. After a return to ambient temperature, the medium is filtered through Celite®, diluted in ether and washed with a 2M HCl solution. The aqueous phase is extracted twice in ether. The combined organic phases are washed with a dilute sodium hydroxide solution and then washed with water, twice, and with a saturated NaCl solution. The organic phase is dried over MgSO4 and then evaporated, to give 1.27 g of a brown oil. The oil is purified by chromatography, to give 0.66 g of the expected compound.
D) 4-(5-Butyl-2-methoxyphenyl)-1,3-thiazol-2-amine
0.19 ml of bromine is added to a solution of 0.66 g of the product of the previous step, in 10 ml of methanol. The medium is stirred for 10 minutes, and then evaporated and taken up in dichloromethane. The organic phase is washed 3 times with water, and then dried over MgSO4. 0.79 g of the expected product is recovered after evaporation. This compound is dissolved in 5 ml of ethanol in the presence of 0.46 g of thiourea and the medium is refluxed for 2 hours 30 minutes. A solid precipitates during the return to ambient temperature. The solid thus collected is rinsed with a small amount of cold ethanol and then with ether. 0.6 g of the hydrobromide is thus recovered.
The solid is suspended in a water/dichloromethane mixture and a return to the base is achieved by adding sodium hydroxide. The aqueous phase is extracted twice in dichloromethane. The combined organic phases are dried over MgSO4 and then evaporated, to give 0.34 g of a yellow oil that crystallizes slowly. The mother liquors are evaporated and then stirred in a water/dichloromethane mixture and a return to the base is achieved by adding sodium hydroxide. The aqueous phase is extracted twice in dichloromethane. The combined organic phases are dried over MgSO4 and then evaporated. The oil obtained is chromatographed on silica gel, to give 0.18 g of the expected compound.
Mp=48° C.
Preparation 1.22 4-(5-Pentafluroethyl-2-methoxyphenyl)-1,3-thiazol-2-amine A) 1-Methoxy-4-pentafluoroethylbenzene
8.3 g of potassium pentafluoropropionate and 9.8 g of CuI are introduced, under an inert atmosphere, into a 500 ml three-necked flask equipped with a Dean-Starck apparatus and a condenser. 90 ml of DMF and 110 ml of toluene are added. The medium is heated to 140° C. under nitrogen; 80 ml of toluene are distilled. The medium is then cooled to AT and then deoxygenated with nitrogen bubbling. 6 g of iodoanisole are then added and the medium is heated at 155° C. for 20 h. After a return to AT, the medium is diluted in 200 ml of a water/ethyl ether mixture. The medium is then filtered through Celite®. The organic phase is washed 3 times with water, dried over MgSO4 and then evaporated, to give 4.3 g of a brown oil.
B) 1-(2-Methoxy-5-pentafluoroethylphenyl)ethanone
7.4 ml of BuLi at 2.5M in hexane are added, at −70° C., to a solution of 3.5 g of 1-methoxy-4-pentafluoroethylbenzene in 50 ml of anhydrous THF. The medium is stirred at −70° C. for 30 min and then at 0° C. for 45 min. 15.5 ml of a 1M solution of zinc chloride in ether are then added. After stirring at 0° C. for 10 min, 1.33 ml of acetyl chloride are added. The medium is then deoxygenated with nitrogen, and 332 mg of palladium benzyl(chloro)bis(triphenylphosphine) in 5 ml of anhydrous THF are introduced. The medium is stirred at 0° C. for 2 h 30 min and then at AT for 72 hours. The medium is run into a 2.5M HCl solution and then extracted in ether. The organic phase is washed with NaHCO3 at 5% in water, with water, and then with a saturated NaCl solution. After drying over MgSO4 and evaporation, the crude is purified by flash chromatography on silica, to give 2.25 g of a white solid.
Mp=47° C.
C) 4-(2-Methoxy-5-pentafluorophenyl)thiazol-2-ylamine
0.5 ml of bromine in solution in 8 ml of methanol is added to a solution of 2.25 g of the product obtained in the previous step, in 10 ml of methanol. The medium is stirred for 10 min and then evaporated and taken up in dichloromethane. The organic phase is washed 3 times with water and then dried over MgSO4. 2.63 g of the brominated product are obtained after evaporation. This compound is dissolved in 15 ml of methanol in the presence of 1.25 g of thiourea, and the medium is refluxed for 2 h. A solid precipitates during the return to AT. The solid thus collected is rinsed with ethyl ether. The solid is suspended in a water/dichloromethane mixture and a return to the base is achieved by adding sodium hydroxide. The aqueous phase is extracted twice in dichloromethane. The combined organic phases are dried over MgSO4 and then evaporated, to give 1.63 g of a yellow solid.
Mp=125° C.
Preparation 1.3 4-(5-Cyclohexyl-2-methoxyphenyl)-1,3-thiazol-2-amine
A) 7.84 g of K2CO3 followed by 3.53 ml of methyl iodide are added to a solution of 5 g of 4-cyclohexylphenol in 60 ml of DMF. The medium is heated at 60° C. overnight. After a return to ambient temperature, the medium is filtered through Celite®, and then diluted in ether and hydrolysed with water. The aqueous phase is acidified and then extracted in 3 times 50 ml of ether. The combined organic phases are washed with a dilute sodium hydroxide solution, and then washed with water, twice, and with a saturated NaCl solution. The organic phase is dried over MgSO4 and then evaporated, to give 4.31 g of the expected compound in the form of a solid.
Mp=67° C.
B) 1-(5-Cyclohexyl-2-methoxyphenyl)ethanone
A suspension of 5.6 g of AlCl3 in 40 ml of dichloromethane is cooled to −10° C. 3 ml of AcCl and 4 g of the compound of the previous step are added. The medium is stirred for 1 hour at −10° C., and then poured into a beaker containing ice mixed with 35% HCl. After separation by settling out, the combined organic phases are dried over MgSO4 and then evaporated, to give 4.54 g of the expected product.
C) 4-(5-Cyclohexyl-2-methoxyphenyl)-1,3-thiazol-2-amine
1.16 ml of bromine are added, dropwise, to a solution of 4.5 g of the product of the previous step, in 25 ml of methanol. The medium is stirred at ambient temperature for 30 minutes, and then becomes very viscous. 5 ml of methanol are added, followed by 3.23 g of thiourea. The medium is refluxed for 2 hours. After a return to ambient temperature, a solid precipitates. The solid is collected, and then rinsed with a small amount of cold methanol. The solid is suspended in a water/dichloromethane mixture and a return to the base is achieved by adding sodium hydroxide. The aqueous phase is extracted twice in dichloromethane. The combined organic phases are dried over MgSO4 and then evaporated, to give 3.33 g of the expected compound in the form of a solid.
Mp=113° C.
Preparation 1.4 4-(2-Methoxy-5-propylphenyl)-1,3-thiazol-2-amine A) 1-(2-Methoxy-5-propylphenyl)ethanone
A suspension of 10.6 g of AlCl3 in 150 ml of dichloromethane is cooled to −10° C. 5.7 ml of AcCl and 6 g of 4-propylanisole are added. The medium is stirred at −10° C. for 30 min, and then poured into a beaker containing ice mixed with 35% HCl. After separation by settling out, the aqueous phase is extracted 3 times in dichloromethane, and the combined organic phases are washed with water and with a saturated NaCl solution, dried over MgSO4 and then evaporated, to give 7.86 g of a brown oil (quant.).
B) 2-Bromo-1-(2-methoxy-5-propylphenyl)ethanone
2.46 ml of bromine diluted in 40 ml of methanol are added, dropwise, to a solution of 7.86 g of the compound obtained in the previous step, in 80 ml of methanol. The medium is stirred at AT for 30 min, and then evaporated. The oil obtained is taken up in dichloromethane, washed 3 times in water and then dried over MgSO4 and evaporated, to give 11.25 g (quant.) of a yellow oil.
C) 4-(2-Methoxy-5-propylphenyl)-1,3-thiazol-2-amine
4.94 g of thiourea are added to a solution of 8 g of the compound obtained in the previous step, in 60 ml of ethanol. The medium is refluxed for 1 h 30 min. The medium is then placed in a refrigerator for 12 h and then filtered. The solid thus collected is rinsed with a small amount of cold ethanol and then with ether. The procedure is repeated a second time. The solid is suspended in a water/dichloromethane mixture and a return to the base is achieved by adding sodium hydroxide. The aqueous phase is extracted twice with dichloromethane. The combined organic phases are dried over MgSO4 and then evaporated, to give 4.89 g of a brown oil that crystallizes slowly (67%).
The mother liquors are evaporated and then stirred in a water/dichloromethane mixture and a return to the base is achieved by adding sodium hydroxide. The aqueous phase is extracted twice in dichloromethane. The combined organic phases are dried over MgSO4 and then evaporated. The oil obtained is chromatographed on silica gel, to give 580 mg of the expected product.
Yield (total): 75%
Mp=84° C.
The compounds of formula (II) described in Table I below are prepared according to the procedures above.
TABLE I
Figure US07767681-20100803-C00043
Mp(° C.)
Preparation No. R1 R2 Salt M
1.1 —OMe -OPr — Mp = 76° C.
1.2 —OMe -nBu — Mp = 48° C.
1.2a —OMe -nBu — Mp = 186° C.
1.3 —OMe
Figure US07767681-20100803-C00044
 		— Mp = 113° C.
1.4 —OMe -nPr — Mp = 84° C.
1.5 —OEt -Et — Mp = 83° C.
1.6 —OMe -Et — Mp = 100° C.
1.7 —OEt
Figure US07767681-20100803-C00045
 		— Mp = 110° C.
1.8 —OMe
Figure US07767681-20100803-C00046
 		— Mp = 110° C.
1.9 —OEt -nBu — Mp = 65° C.
1.10 —OMe CF3 — Mp = 144° C.
1.11 —OMe -iPr — Mp = 109° C.
1.12 —OMe -Me — Mp = 121° C.
1.13
Figure US07767681-20100803-C00047
 		-nBu — Mp = 59° C.
1.14 —OMe
Figure US07767681-20100803-C00048
 		— Mp = 91–93° C.
1.16 —Cl CF3 — Mp = 110° C.
1.17 —OEt Me — Mp = 124° C.
1.18 —OMe —CH(nPr)2 HCl MH+= 305.4
t = 7.61
1.19 -OnPr -nBu — Mp = 63° C.
1.20 —OMe -nHex — Mp = 43° C.
1.21 —OEt -nHex — Mp = 75° C.
1.22 —OMe CF3CF2 — Mp = 125° C.
1.23 —OEt CF3CF2 — MH+= 338
t = 7.88
1.24 —OEt -nPr — Mp = 87° C.
1.25 —OEt cyclopentyl — Mp = 128° C.
Preparation of Aminothiazole Derivatives of Formula (II)
Compounds of formula (II) in which:
Y represents a fluorine atom (preparations 1.26 and 1.27),
R1 and R2 are in the 2-position and 5-position, respectively, with respect to the phenyl.
Preparation 1.26 4-(5-Cyclohexyl-2-methoxyphenyl)-5-fluorothiazol-2-ylamine
3.4 g of Selectfluor© are added to a solution of 2.5 g of the compound obtained in preparation 1.3 described above, in 30 ml of DMF, and the medium is stirred at AT for 2 h. The medium is hydrolysed with 2M ammonia in ethanol, concentrated, and then diluted in water. The crude is filtered, and the solid is taken up in DCM and washed with water, then with 1M sodium hydroxide and with a saturated NaCl solution. After drying of the organic phase over MgSO4 and evaporation, the crude is purified by flash chromatography.
600 mg of the expected product are obtained in the form of a white powder.
Mp=159° C.
Preparation 1.27 4-(5-Propyl-2-methoxyphenyl)-5-fluorothiazol-2-ylamine
The compound is prepared according to preparation 1.26, from the compound of preparation 1.4.
Mp=107° C.
Elemental analysis: % C 59.06 (theoretical 58.63) % H 5.85 (theoretical 5.68) % N 10.22 (theoretical 10.52)
EXAMPLE 1 (Compound No. 9) N-[4-(2-methoxy-5-propylphenyl)thiazol-2-yl]-N′-4-(3-morpholin-4-ylpropyl)piperazin-1-yl]urea
Compound of general formula (I) in which:
R1=2-OMe; R2=5-nPr; R3=3-(morpholin-4-ylpropyl); a=2
Figure US07767681-20100803-C00049
1.1. Preparation of N-[4-(2-methoxy-5-propylphenyl)thiazol-2-yl]-N′-[4-(3-morpholin-4-ylpropyl)piperazin-1-yl]urea
0.18 g of DSC is added to a solution of 0.1 g of 4-(2-(methoxy-5-propylphenyl)-1,3-thiazol-2-amine, obtained in preparation 1.4 above, in 2 ml of DMF, and the medium is stirred at AT for 12 hours. 0.05 g of 1-(morpholin-4-ylpropyl)piperazine is added and the medium is stirred at AT for 3 hours. The medium is hydrolysed with a saturated NaHCO3 solution and then extracted in DCM. The organic phase is washed with water and then with a saturated NaCl solution, and then concentrated. After drying over MgSO4, the solution is concentrated and purified by flash chromatography on silica gel. The solid is taken up in DCM and treated with a 2M solution of HCl in ether, and the suspension is then evaporated, to give 0.077 g of the expected compound in the form of its hydrochloride.
Mp=229° C.
EXAMPLE 2 (Compound No. 35) N-[4-(2-methoxy-5-propylphenyl)thiazol-2-yl]-N′-[4-[2-(3-ethylaminopyrrolidin-1-yl)ethyl]-[1,4]diazepan-1-yl]urea
Compound of general formula (I) in which:
R1=2-OCH3; R2=5-(CH2)2CH3; R3=4-[2-(3-ethylaminopyrrolidin-1-yl)ethyl]; a=3
Figure US07767681-20100803-C00050
2.1 Preparation of N-[4-(2-methoxy-5-propylphenyl)thiazol-2-yl]-N′-[4-(2-chloroacetyl)-[1,4]diazepan-1-yl]urea
4 g of DSC are added to a solution of 3.87 g of 4-(2-(methoxy-5-propylphenyl)-1,3-thiazol-2-amine, obtained in preparation 1.4 above, in 60 ml of DCM, and the medium is stirred at AT for 12 hours. 5.7 g of 2-chloro-1-[1,4]diazepan-1-ylethanone and 3.26 ml of triethylamine are added. The medium is stirred at AT for 3 hours. The medium is hydrolysed with a saturated NaHCO3 solution and then extracted in DCM. The organic phase is washed with water and then with brine, and then concentrated. After drying over MgSO4, the solution is concentrated, to give 5.9 g of the expected compound.
MH+=452 at t=8.53 min
2.2. Preparation of N-[4-(2-methoxy-5-propylphenyl)thiazol-2-yl]-N′-[4-[2-(3-acetylaminopyrrolidin-1-yl)acetyl]-[1,4]diazepan-1-yl]urea (Compound No. 32)
Compound of general formula (I) in which:
R1=2-OCH3; R2=5-(CH2)2CH3; R3=4-[2-(3-acetylaminopyrrolidin-1-yl)acetyl; a=3
0.62 g of 3-acetamidopyrrolidine followed by 0.612 g of K2CO3 are added to a solution of 2 g of 4-(2-chloroacetyl)-[1,4]diazepane-1-carboxylic acid [4-(2-methoxy-5-propylphenyl)thiazol-2-yl]amide prepared in step 2.1, in 10 ml of acetonitrile. The medium is stirred at AT for 48 h. After filtration, the medium is washed with a 1M NaOH solution and then with water and with a saturated NaCl solution. After drying over MgSO4, the solution is concentrated and then purified by flash chromatography, to give 0.95 g of the expected product.
EA: % C=56.94 % H=6.89 % N=14.52 (2H2O)
MH+=543 at t=5.85 min.
2.3. Preparation of N-[4-(2-methoxy-5-propylphenyl)thiazol-2-yl]-N′-[4-[2-(3-ethylaminopyrrolidin-1-yl)ethyl]-[1,4]diazepan-1-yl]urea
2.2 ml of a 65% solution of Red-al in toluene are added, at 0° C., to a solution of 0.79 g of 4-[2-(3-acetylaminopyrrolidin-1-yl)acetyl]-[1,4]-diazepane-1-carboxylic acid [4-(2-methoxy-5-propylphenyl)thiazol-2-yl]amide prepared in step 2.2, in 3 ml of DCM. After stirring at AT for 3 hours, the medium is concentrated and then taken up in DCM and washed with 1M sodium hydroxide, with water, and then with a saturated NaCl solution. After drying over MgSO4, the organic phase is concentrated and then purified by flash chromatography, to give 0.27 g of the expected product.
MH+=515 at t=8.77 min.
EXAMPLE 3 (Compound No. 76) (R)—N-[4-(5-cyclohexyl-2-methoxyphenyl)thiazol-2-yl]-N′-[4-(1-methylpiperidin-3-ylmethyl)piperazin-1-yl]urea
Compound of formula (I) in which:
R1=2-OCH3; R2=5-CyHex; R3=(R)-4-(1-methylpiperidin-3-ylmethyl); a=2
Figure US07767681-20100803-C00051
3.1. Preparation of (R)-3-methanesulphonyloxymethylpiperidine-1-carboxylic acid tert-butyl ester
2.16 ml of methanesulphonyl chloride followed by 3.86 ml of triethylamine are added to a solution of 5 g of (R)-3-hydroxymethylpiperidine-1-carboxylic acid tert-butyl ester in 80 ml of DCM cooled to 0° C. The medium is stirred at 0° C. for 1 h 30 min and 0.7 ml of triethylamine and 0.54 ml of methanesulphonyl chloride are again added. After 30 min at 0° C., the medium is hydrolysed, and the organic phase is washed twice in water and then with a saturated NaCl solution, and then dried over MgSO4. The medium is evaporated, to give 6.8 g of a pale yellow oil.
3.2. Preparation of (R)-3-(4-benzylpiperazin-1-ylmethyl)piperidine-1-carboxylic acid tert-butyl ester
The crude obtained in step 3.1 is dissolved in 75 ml of toluene. 12.16 g of benzylpiperazine are added, and the reaction medium is sealed and then heated at 150° C. for 5 hours. After a return to AT, the medium is diluted in an ether/pentane mixture (1/1), and washed twice with a saturated NaHCO3 solution, twice in water, and then with a saturated NaCl solution. After drying over MgSO4 and evaporation, the crude is purified by flash chromatography on silica gel, to give 5.73 g of the expected solid.
MH+=374 at t=5.26 min
3.3. Preparation of (R)-1-benzyl-4-(1-methylpiperidin-3-ylmethyl)piperazine
5 g of the compound obtained in step 3.2 dissolved in 45 ml of THF are added to a solution of 1 g of LiA1H4 in 45 ml of THF cooled to 0° C. The medium is stirred at AT for two hours and then cooled to 0° C. 0.96 ml of water and then 3 ml of 5M NaOH are added, the medium is then filtered, and the solid is rinsed with ether. The filtrate is evaporated, taken up in ether, and washed twice with a saturated NaHCO3 solution and then with a saturated NaCl solution. After drying over MgSO4 and evaporation, 3.5 g of the desired compound are recovered.
MH+=288 at t=5.68 min
3.4. Preparation of (R)-1-(1-methylpiperidin-3-ylmethyl)piperazine
A solution of 3.46 g of the compound obtained in step 3.3, in 100 ml of methanol, is hydrogenated in the presence of 1.9 g of wet 10% Pd/C under 800 kPa of hydrogen pressure at 40° C. for 3 hours. The medium is filtered and then evaporated, to give 2.26 g of a colourless oil.
3.5. Preparation of (R)—N-[4-(5-cyclohexyl-2-methoxyphenyl)thiazol-2-yl]-N′-[4-(1-methylpiperidin-3-ylmethyl)piperazin-1-yl]urea
The synthesis of this compound is carried out according to the procedure described in Example 1, from 4-(5-cyclohexyl-2-methoxyphenyl)-1,3-thiazol-2-amine described in preparation 1.3 and from the compound obtained in step 3.4.
Mp=108° C.; [α]D 25=−27° (c=1.05; MeOH)
EXAMPLE 4 (Compound No. 70) N-[4-(5-cyclohexyl-2-methoxyphenyl)thiazol-2-yl]-N′-[4-(1-isopropylpiperidin-3-yl)piperazin-1-yl]urea
Compound of formula (I) in which:
R1=2-OCH3; R2=5-CyHex; R3=4-(1-isopropylpiperidin-3-yl); a=2
Figure US07767681-20100803-C00052
4.1. Preparation of 4-(1-benzylpiperidin-3-yl)piperazine-1-carboxylic acid tert-butyl ester
20 ml of a 10% sodium hydroxide solution are added to a suspension of 9.96 g of 1-benzyl-3-piperidone monohydrochloride hydrate in suspension in 200 ml of DCM. The medium is stirred, and the organic phase is separated by settling out and then washed with a saturated NaCl solution. After drying over MgSO4, the organic phase is concentrated. The gum obtained is taken up in 180 ml of DCE, 10.1 g of Boc-piperazine and then 15.9 g of NaBH(OAc)3 are added and the medium is stirred at AT for 12 h. The medium is concentrated and then taken up in EtOAc. The organic phase is washed twice with a saturated NaHCO3 solution, and then with a saturated NaCl solution. After drying over MgSO4, the organic phase is concentrated, to give 18.63 g of the expected product.
Mp=103° C.
4.2. Preparation of 1-(1-benzylpiperidin-3-yl)piperazine
30 g of TFA are added to a solution of 9.2 g of the compound obtained in step 4.1, in 85 ml of DCM. The medium is stirred at AT for 5 h, and then concentrated. The crude obtained is taken up in DCM and then washed 4 times with a 2M sodium hydroxide solution. The organic phase is washed with a saturated NaCl solution. After drying over MgSO4, the organic phase is concentrated, to give 6.32 g of the expected product.
1H NMR: δ (ppm)=7.28 (salt, 5H), 3.43 (salt, 2H), 2.88 (d, 1H), 2.70 (d, 1H), 2.64 (m, 4H), 2.43-2.22 (m, 5H), 1.85-1.58 (m, 4H), 1.39 (ddd, 1H), 1.15 (ddd, 1H).
4.3. Preparation of N-[4-(5-cyclohexyl-2-methoxyphenyl)thiazol-2-yl]-N′-[4-(1-benzylpiperidin-3-yl)piperazin-1-yl]urea (Compound No. 68)
Compound of general formula (I) in which:
R1=2-OCH3; R2=5-CyHex; R3=4-(1-benzylpiperidin-3-yl); a=2
The procedure is identical to that described in Example 1, using the 4-(5-cyclohexyl-2-methoxyphenyl)-1,3-thiazol-2-amine described in preparation 1.3 and the compound obtained in step 4.2.
Mp=90° C.
4.4. Preparation of N-[4-(5-cyclohexyl-2-methoxyphenyl)thiazol-2-yl]-N′-[4-piperidin-3-ylpiperazin-1-yl]urea (Compound No. 69)
Compound of the formula (I) in which:
R1=2-OCH3; R2=5-CyHex; R3=4-(piperidin-3-yl); a=2 1.26 g of chloroethyl chloroformate are added, at 0° C., to a solution of 1.69 g of the compound obtained in step 4.3, in 10 ml of DCE. The medium is returned to AT and is then refluxed for 45 min. The medium is evaporated and then taken up in 10 ml of MeOH and refluxed for 1 h. The crude is filtered, and the solid is rinsed with ether and dried, to give 1.27 g of the expected compound in the form of a trihydrochloride.
Mp=240° C.
MH+=484 at 6.81 min
4.5. Preparation of N-[4-(5-cyclohexyl-2-methoxyphenyl)thiazol-2-yl]-N′-[4-(1-isopropylpiperidin-3-yl)piperazin-1-yl]urea (Compound No. 70)
Compound of formula (I) in which:
R1=2-OCH3; R2=5-CyHex; R3=4-(1-isopropylpiperidin-3-yl); a=2
0.05 ml of acetone followed by 0.15 g of NaBH(OAc)3 are added to a solution of 0.2 g of the compound obtained in step 4.4, in 1.2 ml of DCE, and the medium is stirred at AT for 3 h. 0.1 ml of Et3N and then 0.1 mg of NaBH(OAc)3 are added. The medium is stirred at AT for 12 h. The medium is concentrated and then taken up in EtOAc. The organic phase is washed twice with a saturated NaHCO3 solution, and then with a saturated NaCl solution. After drying over MgSO4, the organic phase is concentrated and then purified by flash chromatography to give 0.11 g of the expected product.
Mp=130° C.
MH+=526 at t=7.06 min
EXAMPLE 5 (Compound No. 74) N-[4-(5-cyclohexyl-2-methoxyphenyl)thiazol-2-yl]-N′-[4-(1-methylpiperidine-2-carbonyl)piperazin-1-yl]urea
Compound of formula (I) in which:
R1=2-OCH3; R2=5-CyHex; R3=4-(1-methylpiperidine-2-carbonyl); a=2
Figure US07767681-20100803-C00053
5.1. Preparation of 4-(1-benzyloxycarbonylpiperidine-2-carbonyl)piperazine-1-carboxylic acid tert-butyl ester
26.6 g of BOP, 13.6 g of 1-(carbobenzyloxy)-2-piperidinecarboxylic acid and then 11.9 ml of triethylamine are added, at 0° C., to a solution of 8 g of 1-Boc-piperazine in 80 ml of acetonitrile. The medium is stirred at AT for 12 hours and then concentrated. The medium is taken up in EtOAc, and washed three times with a saturated Na2CO3 solution and then with a saturated NaCl solution. After drying over MgSO4 and evaporation, 35.45 g of reaction crude are recovered. It is taken up in DCM and then washed twice with 5M sodium hydroxide, and with a saturated NaCl solution, and then dried over MgSO4. After evaporation, the solid is triturated in TBME, filtered, rinsed with TBME, and then dried, to give 17.93 g of the desired compound.
Mp=102° C.
5.2. Preparation of 4-(piperidine-2-carbonyl)piperazine-1-carboxylic acid tert-butyl ester
3.9 ml of cyclohexadiene and then 1.3 g of 10% Pd/C with a 50% water content are added, under an inert atmosphere, to a solution of 1.79 g of the compound obtained in step 5.1, in 14 ml of EtOH. The medium is stirred at AT for 24 hours and then filtered. The filtrate is evaporated, to give 1.02 g of the desired compound.
5.3. Preparation of 4-(1-methylpiperidine-2-carbonyl)piperazine-1-carboxylic acid tert-butyl ester
0.54 ml of 37% aqueous formaldehyde and then 1.41 g of NaBH(OAc)3 are added to a solution of 0.99 g of the compound obtained in step 5.2, in 11 ml of DCE, and the medium is stirred at AT for 12 h. The medium is diluted in DCM and filtered through cotton wool. The organic phase is washed twice with a saturated NaHCO3 solution, and then with a saturated NaCl solution. After drying over MgSO4 and evaporation of the solvents, 0.84 g of the expected product is recovered.
5.4. Preparation of (1-methylpiperidin-2-yl)piperazin-1-ylmethanone
2 ml of TFA are added to a solution of 0.84 g of the compound obtained in step 5.3, in 2 ml of DCM. The medium is stirred at AT for 6 h. The medium is evaporated, taken up several times in DCM, and evaporated so as to entrain the TFA. The medium is taken up in DCM and then treated with a 10% NH4OH solution. The organic phase is dried over MgSO4 and then evaporated, to give 0.15 g of the expected product.
5.5. Preparation of N-[4-(5-cyclohexyl-2-methoxyphenyl)thiazol-2-yl]-N′-[4-(1-methylpiperidine-2-carbonyl)piperazin-1-yl]urea
The procedure is identical to that described in Example 1, using the 4-(5-cyclohexyl-2-methoxyphenyl)-1,3-thiazol-2-amine described in preparation 1.3 and the product obtained in step 5.4.
Mp=135° C.
EXAMPLE 6 (Compound No. 88) N-[4-(5-cyclohexyl-2-methoxyphenyl)thiazol-2-yl]-N′-[4-(1-methylpiperidin-2-ylmethyl)piperazin-1-yl]urea
Compound of formula (I) in which:
R1=2-OCH3; R2=5-CyHex; R3=4-(1-methylpiperidin-2-ylmethyl); a=2
Figure US07767681-20100803-C00054
6.1. Preparation of 4-(1-benzyloxycarbonylpiperidin-2-ylmethyl)piperazine-1-carboxylic acid tert-butyl ester
162 ml of a molar solution of borane in THF are added, at 0° C., to a solution of 14 g of the compound prepared in step 5.1, in 50 ml of THF, over a period of 30 min. The medium is stirred at AT for 24 hours and then hydrolysed by the addition of water at 0° C. After dilution in EtOAc, the medium is washed three times with a saturated Na2CO3 solution, and then with a saturated NaCl solution. After drying over MgSO4 and evaporation, 12.6 g of the expected compound are recovered.
6.2. Preparation of 4-piperidin-2-ylmethylpiperazine-1-carboxylic acid tert-butyl ester
14.5 ml of cyclohexadiene followed by 3.3 g of 10% Pd/C having a 50% water content are added, under an inert atmosphere, to a solution of 6.43 g of the compound obtained in step 6.1, in 50 ml of EtOH. The medium is stirred at AT for 48 hours and then filtered. The filtrate is evaporated, to give 3.63 g of the desired compound.
6.3. Preparation of 4-(1-methylpiperidin-2-ylmethyl)piperazine-1-carboxylic acid tert-butyl ester
1.91 ml of 37% aqueous formaldehyde and a few beads of 4 Å molecular sieve, followed by 5 g of NaBH(OAc)3, are added to a solution of 3.34 g of the compound prepared in step 6.2, in 40 ml of DCE, and the medium is stirred at AT for 48 h. The medium is diluted in DCM, and filtered through cotton wool. The organic phase is washed twice with a saturated NaHCO3 solution, and then with a saturated NaCl solution. After drying over MgSO4 and evaporation of the solvents, 3.28 g of the expected product are recovered.
6.4. Preparation of 1-(1-methylpiperidin-2-ylmethyl)-piperazine
1 ml of a 4M solution of HCl in dioxane is added to a solution of 3.28 g of the compound obtained in step 6.3, in 1 ml of dioxane. The medium is stirred at AT for 48 h. The medium is filtered, and the solid is rinsed with ether and then dried, to give 2.9 g of the desired compound.
6.5. Preparation of N-[4-(5-cyclohexyl-2-methoxyphenyl)thiazol-2-yl]-N′-[4-(1-methylpiperidin-2-yl-methyl)piperazin-1-yl]urea
The procedure is identical to that described in Example 1, using the 4-(5-cyclohexyl-2-methoxyphenyl)-1,3-thiazol-2-amine described in preparation 1.3 and the compound obtained in step 6.4.
Mp=103° C.
TABLE II
Figure US07767681-20100803-C00055
Mp(° C)
No. R1 R2 R3 Y a Salt M
1 —OCH3 —O(CH2)2CH3
Figure US07767681-20100803-C00056
 		H 2 — 144° C.
2 —OCH3 —O(CH2)2CH3
Figure US07767681-20100803-C00057
 		H 2 — 96° C.
3 —OCH3 —(CH2)2CH3
Figure US07767681-20100803-C00058
 		H 2 — 66° C.
4 —OCH3 —(CH2)2CH3
Figure US07767681-20100803-C00059
 		H 2 — 90° C.
5 —OCH3
Figure US07767681-20100803-C00060
Figure US07767681-20100803-C00061
 		H 2 — 66° C.
6 —OCH3 —(CH2)3CH3
Figure US07767681-20100803-C00062
 		H 2 — 133° C.
7 —OCH3 —(CH2)3CH3
Figure US07767681-20100803-C00063
 		H 2 — 45° C.
8 —OCH3
Figure US07767681-20100803-C00064
Figure US07767681-20100803-C00065
 		H 2 — 113° C.
9 —OCH3 —(CH2)2CH3
Figure US07767681-20100803-C00066
 		H 2 HCl 229° C.
10 —OCH3 —(CH2)2CH3
Figure US07767681-20100803-C00067
 		H 3 HCl 234° C.
11 —OCH3 —(CH2)2CH3
Figure US07767681-20100803-C00068
 		H 2 HCl 202° C.
12 —OCH3 —(CH2)2CH3
Figure US07767681-20100803-C00069
 		H 2 HCl 199° C.
13 —OCH3 —(CH2)2CH3
Figure US07767681-20100803-C00070
 		H 2 HCl 230° C.
14 —OCH3 —(CH2)2CH3
Figure US07767681-20100803-C00071
 		H 2 HCl 145° C.
15 —OCH3 —(CH2)2CH3
Figure US07767681-20100803-C00072
 		H 2 HCl 245° C.
16 —OCH3 —(CH2)2CH3
Figure US07767681-20100803-C00073
 		H 2 HCl 239° C.
17 —OCH3 —(CH2)2CH3
Figure US07767681-20100803-C00074
 		H 3 HCl 223° C.
18 —OCH3 —(CH2)2CH3
Figure US07767681-20100803-C00075
 		H 2 HCl 180° C.
19 —OCH3 —(CH2)2CH3
Figure US07767681-20100803-C00076
 		H 2 HCl 180° C.
20 —OCH3 —(CH2)2CH3
Figure US07767681-20100803-C00077
 		H 2 HCl 181° C.
21 —OCH3 —(CH2)2CH3
Figure US07767681-20100803-C00078
 		H 2 HCl 209° C.
22 —OCH3 —(CH2)2CH3
Figure US07767681-20100803-C00079
 		H 2 HCl 200° C.
23 —OCH3 —(CH2)2CH3
Figure US07767681-20100803-C00080
 		H 2 HCl 242° C.
24 —OCH3 —(CH2)2CH3
Figure US07767681-20100803-C00081
 		H 2 HCl 248° C.
25 —OCH3
Figure US07767681-20100803-C00082
Figure US07767681-20100803-C00083
 		H 2 — 114° C.
26 —OCH3 —(CH2)3CH3
Figure US07767681-20100803-C00084
 		H 2 — 65° C.
27 —OCH3 —O(CH2)2CH3
Figure US07767681-20100803-C00085
 		H 2 — 70° C.
28 —OCH3 —(CH2)2CH3
Figure US07767681-20100803-C00086
 		H 2 — 82° C.
29 —OCH3
Figure US07767681-20100803-C00087
Figure US07767681-20100803-C00088
 		H 2 HCl MH+ = 534 at 6.14 min
30 —OCH3
Figure US07767681-20100803-C00089
Figure US07767681-20100803-C00090
 		H 2 — MH+ = 498 at 6.52 min
31 —OCH3 —(CH2)2CH3
Figure US07767681-20100803-C00091
 		H 2 — 89° C.
32 —OCH3 —(CH2)2CH3
Figure US07767681-20100803-C00092
 		H 3 — MH+ = 543 at 5.85 min
33 —OCH3 —(CH2)2CH3
Figure US07767681-20100803-C00093
 		H 2 — MH+ = 501 at 5.03 min
34 —OCH3 —(CH2)2CH3
Figure US07767681-20100803-C00094
 		H 3 — MH+ = 486 at 6.04 min
35 —OCH3 —(CH2)2CH3
Figure US07767681-20100803-C00095
 		H 3 HCl MH+ = 515 at 8.77 min
36 —OCH3 —(CH2)2CH3
Figure US07767681-20100803-C00096
 		F 2 — 63° C.
37 —OCH3 —(CH2)2CH3
Figure US07767681-20100803-C00097
 		H 2 — 63° C.
38 —OCH3 —(CH2)5CH3
Figure US07767681-20100803-C00098
 		H 2 HCl MH+ = 500 at 6.99 min
39 —OCH2CH3 —CH2CH3
Figure US07767681-20100803-C00099
 		H 2 — 96° C.
40 —OCH2CH3 —(CH2 3CH3
Figure US07767681-20100803-C00100
 		H 2 — 130° C.
41 —OCH2CH3
Figure US07767681-20100803-C00101
Figure US07767681-20100803-C00102
 		H 2 — 89° C.
42 —OCH3 —CH2CH3
Figure US07767681-20100803-C00103
 		H 2 — 100° C.
43 —OCH3
Figure US07767681-20100803-C00104
Figure US07767681-20100803-C00105
 		H 2 — 106° C.
44 —OCH3
Figure US07767681-20100803-C00106
Figure US07767681-20100803-C00107
 		H 2 — 98° C.
45 —OCH3 —(CH2)3CH3
Figure US07767681-20100803-C00108
 		H 2 — 90° C.
46 —OCH3 —(CH2)3CH3
Figure US07767681-20100803-C00109
 		H 2 — 69° C.
47 —OCH3
Figure US07767681-20100803-C00110
Figure US07767681-20100803-C00111
 		H 2 — 103° C.
48 —OCH3
Figure US07767681-20100803-C00112
Figure US07767681-20100803-C00113
 		H 2 — 98° C.
49 —OCH2CH3
Figure US07767681-20100803-C00114
Figure US07767681-20100803-C00115
 		H 2 — 109° C.
50 —OCH2CH3
Figure US07767681-20100803-C00116
Figure US07767681-20100803-C00117
 		H 2 — 108° C.
51 —OCH2CH3
Figure US07767681-20100803-C00118
Figure US07767681-20100803-C00119
 		H 2 — 106° C.
52 —OCH2CH3
Figure US07767681-20100803-C00120
Figure US07767681-20100803-C00121
 		H 2 — 96° C.
53 —OCH2CH3
Figure US07767681-20100803-C00122
Figure US07767681-20100803-C00123
 		H 2 — 75° C.
54 —OCH2CH3 —(CH2)3CH3
Figure US07767681-20100803-C00124
 		H 2 — 140° C.
55 —OCH3
Figure US07767681-20100803-C00125
Figure US07767681-20100803-C00126
 		H 2 — 102° C.
56 —OCH2CH3 —(CH2)3CH3
Figure US07767681-20100803-C00127
 		H 2 — 91° C.
57 —OCH2CH3
Figure US07767681-20100803-C00128
Figure US07767681-20100803-C00129
 		H 2 — 110° C.
58 —OCH3
Figure US07767681-20100803-C00130
Figure US07767681-20100803-C00131
 		F 2 HCl MH+ = 516 at 6.79 min
59 —OCH3
Figure US07767681-20100803-C00132
Figure US07767681-20100803-C00133
 		F 2 HCl MH+ = 515 at 6.01 min
60 —OCH3
Figure US07767681-20100803-C00134
Figure US07767681-20100803-C00135
 		F 2 HCl MH+ = 532 at 6.91 min
61 —OCH3
Figure US07767681-20100803-C00136
Figure US07767681-20100803-C00137
 		H 2 — 118° C.
62 —OCH3 —(CH2)3CH3
Figure US07767681-20100803-C00138
 		H 2 — 84° C.
63 —OCH3
Figure US07767681-20100803-C00139
Figure US07767681-20100803-C00140
 		H 2 — 79° C.
64 —OCH3
Figure US07767681-20100803-C00141
Figure US07767681-20100803-C00142
 		H 2 — 97° C.
65 —OCH3
Figure US07767681-20100803-C00143
Figure US07767681-20100803-C00144
 		H 2 — 172° C.
66 —oCH3
Figure US07767681-20100803-C00145
Figure US07767681-20100803-C00146
 		H 2 — 107° C.
67 —OCH3
Figure US07767681-20100803-C00147
Figure US07767681-20100803-C00148
 		H 2 — 83° C.
68 —OCH3
Figure US07767681-20100803-C00149
Figure US07767681-20100803-C00150
 		H 2 — 90 ° C.
69 —OCH3
Figure US07767681-20100803-C00151
Figure US07767681-20100803-C00152
 		H 2 3 HCl 240° C.
70 —OCH3
Figure US07767681-20100803-C00153
Figure US07767681-20100803-C00154
 		H 2 — 130° C.
71 —OCH3
Figure US07767681-20100803-C00155
Figure US07767681-20100803-C00156
 		H 2 — 127° C.
72 —OCH3
Figure US07767681-20100803-C00157
Figure US07767681-20100803-C00158
 		H 2 — 125° C.
73 —OCH3
Figure US07767681-20100803-C00159
Figure US07767681-20100803-C00160
 		H 2 — 122° C.
74 —OCH3
Figure US07767681-20100803-C00161
Figure US07767681-20100803-C00162
 		H 2 — 135° C.
75 —OCH3
Figure US07767681-20100803-C00163
Figure US07767681-20100803-C00164
 		H 2 — 107° C.
76 —OCH3
Figure US07767681-20100803-C00165
Figure US07767681-20100803-C00166
 		H 2 — 108° C.
77 —OCH3 —(CH2)3CH3
Figure US07767681-20100803-C00167
 		H 2 — 85° C.
78 —OCH3
Figure US07767681-20100803-C00168
Figure US07767681-20100803-C00169
 		H 2 — 94° C.
79 —OCH3 —(CH2)5CH3
Figure US07767681-20100803-C00170
 		H 2 — 68° C.
80 —OCH2CH3 —(CH2)5CH3
Figure US07767681-20100803-C00171
 		H 2 — 65° C.
81 —OCH2CH3 —(CH2)3CH3
Figure US07767681-20100803-C00172
 		H 2 — 75° C.
82 —OCH3
Figure US07767681-20100803-C00173
Figure US07767681-20100803-C00174
 		H 2 — 85° C.
83 —OCH2CH3 —(CH2)2CH3
Figure US07767681-20100803-C00175
 		H 2 — 74° C.
84 —OCH2CH3
Figure US07767681-20100803-C00176
Figure US07767681-20100803-C00177
 		H 2 — 92° C.
85 —O(CH2)2CH3 —CH2CH3
Figure US07767681-20100803-C00178
 		H 2 — 73° C.
86 —OCH3 —CH2CH3
Figure US07767681-20100803-C00179
 		H 2 — 86° C.
87 —OCH2CH3
Figure US07767681-20100803-C00180
Figure US07767681-20100803-C00181
 		H 2 — 98° C., 103° C.
88 —OCH3
Figure US07767681-20100803-C00182
Figure US07767681-20100803-C00183
 		H 2 — 103° C.
89 —OCH3
Figure US07767681-20100803-C00184
Figure US07767681-20100803-C00185
 		H 2 — 121° C.
90 —OCH3
Figure US07767681-20100803-C00186
Figure US07767681-20100803-C00187
 		H 2 — 119° C.
91 —OCH3 —CH3
Figure US07767681-20100803-C00188
 		H 2 — 95° C.
92 —OCH3
Figure US07767681-20100803-C00189
Figure US07767681-20100803-C00190
 		H 2 — 85° C.
93 —OCH3
Figure US07767681-20100803-C00191
Figure US07767681-20100803-C00192
 		H 2 — 125° C.
94 —OCH3
Figure US07767681-20100803-C00193
Figure US07767681-20100803-C00194
 		H 3 — 112° C.
95 —OCH3
Figure US07767681-20100803-C00195
Figure US07767681-20100803-C00196
 		H 2 — 101° C.
96 —OCH3
Figure US07767681-20100803-C00197
Figure US07767681-20100803-C00198
 		H 2 — 215° C.
97 —OCH3
Figure US07767681-20100803-C00199
Figure US07767681-20100803-C00200
 		H 2 — 103° C.
98 —OCH3
Figure US07767681-20100803-C00201
Figure US07767681-20100803-C00202
 		H 2 — 106° C.
99 —OCH3
Figure US07767681-20100803-C00203
Figure US07767681-20100803-C00204
 		H 2 — 128° C.
100 —OCH3
Figure US07767681-20100803-C00205
Figure US07767681-20100803-C00206
 		H 3 — 88° C.
101 —OCH3
Figure US07767681-20100803-C00207
Figure US07767681-20100803-C00208
 		H 2 — 122° C.
102 —OCH3
Figure US07767681-20100803-C00209
Figure US07767681-20100803-C00210
 		H 2 — 146° C.
103 —OCH3
Figure US07767681-20100803-C00211
Figure US07767681-20100803-C00212
 		H 2 — 132° C.
Mp
(° C.) Other
No. R1 R2 R3 Y a Salt M analysis
104 —OCH3
Figure US07767681-20100803-C00213
Figure US07767681-20100803-C00214
 		H 2 — 132° C.
105 —OCH3
Figure US07767681-20100803-C00215
Figure US07767681-20100803-C00216
 		H 2 — 119° C. —
106 —OCH3
Figure US07767681-20100803-C00217
Figure US07767681-20100803-C00218
 		H 2 — 118° C. —
107 —OCH3
Figure US07767681-20100803-C00219
Figure US07767681-20100803-C00220
 		H 2 — — MH+ = 590 at 7.52 min
108 —OCH3
Figure US07767681-20100803-C00221
Figure US07767681-20100803-C00222
 		H 2 — — C:63.17 H:7.20 N:13.51
109 —OCH2CH3
Figure US07767681-20100803-C00223
Figure US07767681-20100803-C00224
 		H 2 — 111° C. —
110 —OCH2CH3
Figure US07767681-20100803-C00225
Figure US07767681-20100803-C00226
 		H 2 — 113° C. —
111 —OCH3
Figure US07767681-20100803-C00227
Figure US07767681-20100803-C00228
 		H 2 — 98° C. aD = −6.2° c = 1.0 M MeOH
112 —OCH3
Figure US07767681-20100803-C00229
Figure US07767681-20100803-C00230
 		H 2 — 158° C. —
No. R1 R2 R3 Y a Salt M
113 —OCH3
Figure US07767681-20100803-C00231
Figure US07767681-20100803-C00232
 		H 2 — 158° C.
114 —OCH3
Figure US07767681-20100803-C00233
Figure US07767681-20100803-C00234
 		H 2 — 125° C.
115 —OCH3
Figure US07767681-20100803-C00235
Figure US07767681-20100803-C00236
 		H 2 — 157° C.
116 —OCH3
Figure US07767681-20100803-C00237
Figure US07767681-20100803-C00238
 		H 2 — 119° C.
117 —OCH3
Figure US07767681-20100803-C00239
Figure US07767681-20100803-C00240
 		H 2 — 81° C.
118 —OCH3
Figure US07767681-20100803-C00241
Figure US07767681-20100803-C00242
 		H 2 — 91° C.
119 —OCH3
Figure US07767681-20100803-C00243
Figure US07767681-20100803-C00244
 		H 2 — 117° C.
120 —OCH3
Figure US07767681-20100803-C00245
Figure US07767681-20100803-C00246
 		H 2 — 78° C.
The compounds according to the invention were subjected to pharmacological assays in order to determine their modulatory effect on the activity of chemokine receptors.
Chemokines are low molecular weight proteins that belong to the pro-inflammatory cytokine family and are involved in leukocyte and endothelial cell chemotaxis. Chemokines control many biological processes and are associated with inflammatory disorders that appear during states of stress, during injuries or during infections; modulating the effect of chemokines makes it possible to prevent or treat pathologies such as asthma, arthritis, allergies, autoimmune diseases, atherosclerosis or angiogenesis (C. D. Paavola et al., J. Biol. Chem., 1998, 273, (50), 33157-33165).
Among the chemokines, hMCP-1 (human monocyte chemotactic protein) which belongs to the CC chemokine group and which is a natural agonist of the CCR2b receptor, is distinguished.
The inhibitory activity of the compounds according to the invention on cells expressing the human CCR2b receptor was measured. The concentration of natural agonist hMCP-1 that inhibits 50% (IC50) of the activity of the CCR2b receptor is 0.57 nM. The compounds according to the invention exhibit an IC50 that is generally less than 0.1 μM.
For example, Compound No. 14 exhibited an IC50 of 0.0033 μM;
Compound No. 28 exhibited an IC50 of 0.028 μM;
Compound No. 55 exhibited an IC50 of 0.014 μM.
The inhibition of chemotaxis was also measured on human THP-1 monocyte cells (sold by DSMZ—Germany), using a technique adapted from that described by A. Albini et al., Cancer Res., 1987, 47, 3239-3245. Under these conditions, hMCP-1 exhibits an IC50 of 6 nM. The compounds according to the invention exhibit an IC50 that is generally less than 1 μM.
The inhibition of chemotaxis by the compounds according to the invention is a sign of their antagonistic activity on chemokine receptors, and in particular the CCR2b receptor.
It therefore appears that the compounds according to the invention are antagonist of the effect of chemokines, in particular of hMCP-1.
The inhibitory activity of the compounds according to the invention was also measured on PBMCs (peripheral blood mononuclear cells) infected with the HIV-1 Bal virus, according to a technique adapted from that described by V. Dolle et al., J. Med. Chem., 2000, 43, 3949, 3962. According to this technique, the PBMCs are infected with HIV-1 Bal and the compounds to be tested are then added to the culture medium for 5 days. At the end of this exposure, the amount of reverse transcriptase in the supernatant is measured, which correlates with the level of viral replication in the cells.
Under these conditions, AZT, a reference molecule which inhibits viral replication, exhibits an IC50 of less than 1 μM. Compounds according to the invention also exhibit IC50 values of less than 1 μM. For example, Compound No. 30 showed an IC50 of 0.6 μM.
The compounds according to the invention can therefore be used for preparing medicinal products, in particular medicinal products that are agonists of the effect of chemokines.
Thus, according to another of its aspects, a subject of the present invention is medicinal products which comprise a compound of formula (I) or an addition salt of the latter with a pharmaceutically acceptable acid, or else a hydrate or a solvate.
These medicinal products find their use in therapeutics, in particular in the prevention and treatment of various pathologies, such as:
    • acute and chronic immunoinflammatory diseases and syndromes, such as atherosclerosis, restenoses, chronic pulmonary diseases, in particular COPD (chronic obstructive pulmonary disease); respiratory distress syndrome; bronchial hyperactivity; colitis; silicosis; fibrous pathologies, pulmonary fibroses, cystic fibroses; viral or bacterial infections, AIDS, meningitis, malaria, leprosy, tuberculosis, herpes, cytomegalovirus infections; septic shocks, septicaemia, endotoxic shocks; transplant rejections; bone pathologies such as osteoporosis, osteoarthritis; conjunctivitis; atypical or contact dermatitis; eczema; glomerulonephritis; pancreatitis; ulcerative colitis, autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, amyotrophic lateral sclerosis, Crohn's disease, lupus erythematosus, scleroderma, psoriasis; Parkinson's disease; Alzheimer's disease; diabetes; cachexia; obesity;
    • the treatment of pain, in particular neuropathic and inflammatory pain;
    • allergic diseases such as allergic respiratory diseases, asthma, rhinitis, pulmonary hypersenstitivity, delayed hypersensitivity;
    • diseases and disorders in which angiogenic processes are involved, such as cancers (intratumoral angiogenesis), retinal diseases (age-related macular degeneration: ARMD);
    • cardiac pathologies: haemodynamic shock; cardiac ischaemias; post-ischaemic reperfusion attacks; myocardial infarction, coronary thrombosis, heart failure, angina pectoris.
According to another of its aspects, the present invention relates to pharmaceutical compositions comprising, as active principle, a compound according to the invention. These pharmaceutical compositions contain an effective dose of at least one compound according to the invention, or a pharmaceutically acceptable salt, or a hydrate or solvate of said compound, and also at least one pharmaceutically acceptable excipient.
Said excipients are chosen, according to the pharmaceutical form and the method of administration desired, from the usual excipients that are known to those skilled in the art.
In the pharmaceutical compositions of the present invention for oral, sublingual, subcutaneous, intamuscular, intravenous, topical, local, intratracheal, intranasal, transdermal or rectal administration, the active principle of formula (I) above, or its possible salt, solvate or hydrate, can be administered in unit administration form, as a mixture with conventional pharmaceutical excipients, to animals and to human beings for the prophylaxis or the treatment of the disorders or of the diseases above.
The suitable unit administration forms comprise oral forms such as tablets, soft or hard gelatin capsules, powders, granules and oral solutions or suspensions, sublingual, buccal, intratracheal, intraocular and intranasal administration forms, forms for administration by inhalation, topical, transdermal, subcutaneous, intramuscular or intravenous administration forms, rectal administration forms, and implants. For topical application, the compounds according to the invention can be used in creams, gels, ointments or lotions.
By way of example, a unit administration form of a compound according to the invention in the form of a tablet can comprise the following constituents:
Compound according to the invention 50.0 mg
Mannitol 223.75 mg
Sodium croscaramellose 6.0 mg
Corn starch 15.0 mg
Hydroxypropylmethylcellulose 2.25 mg
Magnesium stearate 3.0 mg
When given orally, the dose of active principle administered per day can reach 0.1 to 1000 mg/kg, taken in one or more doses.
There may be specific cases where higher or lower dosages are appropriate; such dosages do not depart from the context of the invention. According to the usual practice, the dosage appropriate for each patient is determined by the physician according to the method of administration, and the weight and response of said patient.
According to another of its aspects, the present invention also relates to a method of treating the pathologies indicated above, which comprises the administration of an effective dose of a compound according to the invention, or one of its pharmaceutically acceptable salts or hydrates or solvates, to a patient.

Claims (9)

1. A compound of formula (I):
Figure US07767681-20100803-C00247
wherein
R1 is selected from the group consisting of halogen, (C1-C8)alkyl, trifluoro(C1-C4)alkyl, —OH, —O—(C1-C8)alkyl, —O-trifluoro(C1-C8)alkyl, —O—(C3-C10)cycloalkyl(C1-C8)alkyl, —O—(C3-C10)cycloalkyl, —O—CH2—CH═CH2 and (C1-C4)alkylthio;
R2 is selected from the group consisting of halogen, —OH, (C1-C8)alkyl, trifluoro(C1-C4)alkyl, perfluoro(C1-C4)alkyl, (C3-C10)cycloalkyl, —O—(C1-C8)alkyl, —O—(C3-C10)— cycloalkyl(C1-C8)alkyl, —O—(C3-C10)cycloalkyl, —O—CH2—CH═CH2 and (C3-C8)cycloalkyl(C1-C8)alkyl;
Y represents a hydrogen atom or a halogen;
R3 represents:
a1) a group of formula —(CH2)p-A
in which p represents 0, 1, 2, 3 or 4, and:
when p represents 2, 3 or 4, A represents a group of formula:
Figure US07767681-20100803-C00248
in which R6 is selected from the group consisting of H, F, (C1-C4)alkyl, —(CH2)OH, —(CH2)nO(C1-C4)alkyl and —(CH2)nNR4R5, where n represents 0, 1 or 2, and R4 and R5 represent, independently of one another, a hydrogen atom, or a (C1-C8)alkyl, —CO(C1-C4)alkyl or —CO—O—(C1-C8)alkyl group;
or, when p represents 1, 2, 3 or 4, A represents a group of formula:
Figure US07767681-20100803-C00249
in which R7 is selected from the group consisting of H, (C1-C8)alkyl, —CO—(C1-C8)alkyl, benzyl, —CO—O—(C1-C8)alkyl, —CO—O-benzyl, —CO-phenyl, —CO-hetero aryl, —CO—(C3-C10)-cycloalkyl, —SO2—(C1-C8)alkyl, —SO2—(C3-C8)cycloalkyl and —SO2-heteroaryl;
or, when p represents 0, 1, 2, 3 or 4, A represents a group of formula:
Figure US07767681-20100803-C00250
said group being optionally substituted with a (C1-C4)alkyl group;
a2) a group of formula —(CH2)p—CO-A
in which p represents 1, 2, 3 or 4,
A represents a group of formula:
Figure US07767681-20100803-C00251
in which R4, R5 and R6 are as defined above; or
a3) a group of formula —CO(CH2)p-A
in which p represents 0, 1, 2, 3 or 4
when p represents 1, 2, 3 or 4, A represents a group of formula:
Figure US07767681-20100803-C00252
—NR4R5,
in which R4, R5 and R6 are as defined above;
or, when p represents 0, 1, 2, 3 or 4, A represents a group of formula:
Figure US07767681-20100803-C00253
in which R7 is as defined above;
or, when p represents 0, 1, 2, 3 or 4, A represents a group of formula:
Figure US07767681-20100803-C00254
said group being optionally substituted with a (C1-C4)alkyl group;
a represents 2 or 3;
or an acid addition salt thereof.
2. A compound according to claim 1, of formula (I.a):
Figure US07767681-20100803-C00255
wherein:
R1, R2, R3 and Y are as defined in claim 1,
or an acid addition salt thereof.
3. A compound according to claim 1, of formula (I.b):
Figure US07767681-20100803-C00256
in which R1, R2, Y, p and A are as defined in claim 1,
or an acid addition salt thereof.
4. A compound according to claim 1, wherein R1 represents a —O—(C1-C8)alkyl group.
5. A compound according to claim 1, wherein R2 represents a (C1-C8)alkyl, (C3-C10)cycloalkyl, perfluoro(C1-C4)alkyl or —O—(C1-C8)alkyl group.
6. A compound according to claim 1 selected from the group consisting of:
(R)—N-[4-(5-cyclohexyl-2-methoxyphenyl)thiazol-2-yl]-N′-[4-(1-methylpiperidin-3-ylmethyl)piperazin-1-yl]urea,
N-[4-(2-methoxy-5-propoxyphenyl)thiazol-2-yl]-N′-[4-(2-morpholin-4-ylethyl)piperazin-1-yl]urea,
N-[4-(2-methoxy-5-propylphenyl)thiazol-2-yl]-N′-[4-(3-piperidin-1-ylpropyl)piperazin-1-yl]urea,
N-[4-(2-methoxy-5-propylphenyl)thiazol-2-yl]-N′-[4-(2-dimethylaminoethyl)piperazin-1-yl]urea,
N-[4-(2-methoxy-5-propylphenyl)thiazol-2-yl]-N′-[4-(2-thiophen-2-ylethyl)piperazin-1-yl]urea,
N-[4-(2-methoxy-5-propylphenyl)thiazol-2-yl]-N′-[4-[2-(tetrahydrofuran-2-yl)ethyl]piperazin-1-yl]urea,
N-[4-(2-methoxy-5-propylphenyl)thiazol-2-yl]-N′-[4-[2-(3-ethylaminopyrrolidin-1-yl)ethyl]piperazin-1-yl]urea,
N-[4-(2-methoxy-5-pentafluoroethylphenyl)thiazol-2-yl]-N′-[4-(2-pyrrolidin-1-ylethyl)piperazin-1-yl]urea,
N-[4-(5-cyclohexyl-2-methoxyphenyl)thiazol-2-yl]-N′-[4-(2-pyrrolidin-1-ylethyl)piperazin-1-yl]urea,
N-[4-(5-cyclohexyl-2-methoxyphenyl)thiazol-2-yl]-N′-[4-(2-oxo-2-morpholino-4-ylethyl)piperazin-1-yl]urea,
N-[4-(5-cyclohexyl-2-ethoxyphenyl)thiazol-2-yl]-N′-[4-(2-oxo-2-morpholino-4-ylethyl)piperazin-1-yl]urea,
(S)N-[4-(5-cyclohexyl-2-methoxyphenyl)thiazol-2-yl]-N′-[4-(1-sulphomethylpiperidin-3-ylmethyl)piperazin-1-yl]urea, and
N-[4-(5-cyclohexyl-2-methoxyphenyl)thiazol-2-yl]-N′-[4-(1-oxo-1-(1-oxopyridin-2-yl)meth-1-ylpiperidin-3-ylmethyl)piperazin-1-yl]urea;
or an acid addition salt thereof.
7. A pharmaceutical composition comprising a compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof; and at least one pharmaceutically acceptable excipient.
8. A pharmaceutical composition comprising a compound according to claim 6, or a pharmaceutically acceptable salt thereof; and at least one pharmaceutically acceptable excipient.
9. The compound according to claim 1, selected from the group consisting of:
Figure US07767681-20100803-C00257
Figure US07767681-20100803-C00258
Figure US07767681-20100803-C00259
Figure US07767681-20100803-C00260
Figure US07767681-20100803-C00261
Figure US07767681-20100803-C00262
Figure US07767681-20100803-C00263
Figure US07767681-20100803-C00264
Figure US07767681-20100803-C00265
or a pharmaceutically acceptable salt thereof.
US11/649,316 2004-07-09 2007-01-03 2-Carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof Expired - Fee Related US7767681B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0407695 2004-07-09
FR0407695A FR2872813B1 (en) 2004-07-09 2004-07-09 2-CARBAMID-4-PHENYLTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
PCT/FR2005/001729 WO2006016039A1 (en) 2004-07-09 2005-07-05 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2005/001729 Continuation WO2006016039A1 (en) 2004-07-09 2005-07-05 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof

Publications (2)

Publication Number Publication Date
US20070179126A1 US20070179126A1 (en) 2007-08-02
US7767681B2 true US7767681B2 (en) 2010-08-03

Family

ID=34948475

Family Applications (1)

Application Number Title Priority Date Filing Date
US11/649,316 Expired - Fee Related US7767681B2 (en) 2004-07-09 2007-01-03 2-Carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof

Country Status (26)

Country Link
US (1) US7767681B2 (en)
EP (1) EP1771425B1 (en)
JP (1) JP2008505872A (en)
KR (1) KR20070030271A (en)
CN (1) CN101001847A (en)
AR (1) AR054397A1 (en)
AT (1) ATE395342T1 (en)
AU (1) AU2005271130A1 (en)
BR (1) BRPI0513184A (en)
CA (1) CA2571143A1 (en)
CR (1) CR8824A (en)
DE (1) DE602005006815D1 (en)
EA (1) EA011076B1 (en)
EC (1) ECSP067110A (en)
ES (1) ES2304719T3 (en)
FR (1) FR2872813B1 (en)
IL (1) IL180284A0 (en)
MA (1) MA28734B1 (en)
MX (1) MX2007000367A (en)
NO (1) NO20070224L (en)
PE (1) PE20060487A1 (en)
TN (1) TNSN06439A1 (en)
TW (1) TW200621737A (en)
UY (1) UY29007A1 (en)
WO (1) WO2006016039A1 (en)
ZA (1) ZA200700705B (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004228028B2 (en) 2003-04-03 2009-12-10 The Regents Of The University Of California Improved inhibitors for the soluble epoxide hydrolase
FR2854158B1 (en) 2003-04-25 2006-11-17 Sanofi Synthelabo 2-ACYLAMINO-4-PHENYLETHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
CA2559665A1 (en) 2004-03-16 2005-09-29 The Regents Of The University Of California Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids
FR2876692B1 (en) 2004-10-19 2007-02-23 Sanofi Aventis Sa 2-AMIDO-4-PHENYLTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
CN101084216B (en) 2004-10-20 2011-09-14 加利福尼亚大学董事会 Inhibitors for the soluble epoxide hydrolase
GB0428327D0 (en) * 2004-12-24 2005-02-02 Astrazeneca Ab Method
BRPI0519288A2 (en) 2004-12-24 2009-01-06 Astrazeneca Ab heterocyclic compounds as ccr2b antagonists
US8067415B2 (en) * 2005-11-01 2011-11-29 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of CCR2
US20100016289A1 (en) * 2005-11-01 2010-01-21 Kevin Sprott Compounds Useful as Antagonists of CCR2
US8067457B2 (en) * 2005-11-01 2011-11-29 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of CCR2
FR2895989B1 (en) 2006-01-06 2010-04-30 Sanofi Aventis 2-CARBAMID-4-PHENYLTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
TW200808723A (en) * 2006-03-13 2008-02-16 Univ California Conformationally restricted urea inhibitors of soluble epoxide hydrolase
US7935715B2 (en) 2006-07-28 2011-05-03 Boehringer Ingelheim International Gmbh Compounds which modulate the CB2 receptor
MX2009002888A (en) 2006-09-25 2009-03-31 Boehringer Ingelheim Int Compounds which modulate the cb2 receptor.
US8173638B2 (en) * 2006-11-21 2012-05-08 Boehringer Ingelheim International Gmbh Compounds which modulate the CB2 receptor
WO2008120759A1 (en) * 2007-03-30 2008-10-09 Japan Tobacco Inc. Urea compound and use thereof
JP5492092B2 (en) 2007-11-07 2014-05-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Compounds that modulate the CB2 receptor
JP5749162B2 (en) 2008-07-10 2015-07-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Sulfone compounds that modulate the CB2 receptor
KR20110063438A (en) 2008-09-25 2011-06-10 베링거 인겔하임 인터내셔날 게엠베하 Sulfonyl compounds which selectively modulate the cb2 receptor
US8299103B2 (en) 2009-06-15 2012-10-30 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
EP2443107B1 (en) 2009-06-16 2018-08-08 Boehringer Ingelheim International GmbH Azetidine 2 -carboxamide derivatives which modulate the cb2 receptor
EP2480544A1 (en) 2009-09-22 2012-08-01 Boehringer Ingelheim International GmbH Compounds which selectively modulate the cb2 receptor
US9315454B2 (en) 2010-01-15 2016-04-19 Boehringer Ingelheim International Gmbh Compounds which modulate the CB2 receptor
WO2012054093A2 (en) 2010-01-29 2012-04-26 The Regents Of The University Of California Acyl piperidine inhibitors of soluble epoxide hydrolase
JP5746228B2 (en) 2010-03-05 2015-07-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Tetrazole compound that selectively modulates CB2 receptor
CA2793311C (en) 2010-03-17 2019-01-15 Taivex Therapeutics Inc. Modulators of hec1 activity and methods therefor
WO2012012307A1 (en) 2010-07-22 2012-01-26 Boehringer Ingelheim International Gmbh Sulfonyl compounds which modulate the cb2 rece
US11071736B2 (en) 2011-11-21 2021-07-27 Taivex Therapeutics Corporation Modulators of HEC1 activity and methods therefor
EP2803668A1 (en) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
CN112279748A (en) * 2020-12-24 2021-01-29 浙江巨化技术中心有限公司 Preparation method of 1,1,2,2-tetrafluoroethane

Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0001727A2 (en) 1977-10-19 1979-05-02 Pierre Fabre S.A. New derivatives of 4-phenyl-2-(2',2',2-trichlorethoxycarboxamido)-thiazole useful as medicaments, pharmaceutical compositions containing them and process for the preparation of these compounds
WO1987001706A2 (en) 1985-09-12 1987-03-26 The Upjohn Company C20 through c26 amino steroids
EP0518731A1 (en) 1991-06-05 1992-12-16 Sanofi Heterocyclic derivatives of substituted 2-acylamino 5-thiazole, their preparation and pharmaceutical compositions containing them
EP0519449A1 (en) 1991-06-21 1992-12-23 Boehringer Mannheim Italia S.P.A. 2-Amino-4-aryl thiazoles with antiasthmatic and antiinflammatory activities on the respiratory tract
EP0611766A1 (en) 1993-02-19 1994-08-24 Sanofi Polysubstituted 2-amido thiazoles derivatives, process for their preparation, pharmaceutical compositions and utilization for the preparation of a medicament
WO1999015525A1 (en) 1997-09-19 1999-04-01 Sanofi-Synthelabo Carboxamidothiazole derivatives, preparation, pharmaceutical compositions containing them
WO2002051397A1 (en) 2000-12-22 2002-07-04 Ishihara Sangyo Kaisha, Ltd. Aniline derivatives or salts thereof and cytokine production inhibitors containing the same
US20020115863A1 (en) 1999-12-17 2002-08-22 Dinesh Patel Novel succinate compounds, compositions and methods of use and preparation
US20020119962A1 (en) 1999-12-17 2002-08-29 Jacobs Jeffrey W. Novel urea compounds, compositions and methods of use and preparation
US6506751B1 (en) 1999-11-12 2003-01-14 Millennium Pharmaceuticals, Inc. Thiazolidinone compounds useful as chemokine inhibitors
WO2003015778A1 (en) * 2001-08-17 2003-02-27 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003057145A2 (en) 2001-12-31 2003-07-17 Guilford Pharmaceuticals Inc. SUBSTITUTED 4,9-DIHYDROCYCLOPENTA[imn]PHENANTHRIDINE-5-ONES DERIVATIVES THEREOF AND THEIR USES
WO2003088908A2 (en) 2002-04-19 2003-10-30 Bristol-Myers Squibb Company Heterocyclo inhibitors of potassium channel function
WO2003104230A1 (en) 2002-06-07 2003-12-18 協和醱酵工業株式会社 Bicyclic pyrimidine derivatives
WO2004096798A2 (en) 2003-04-25 2004-11-11 Sanofi-Aventis Derivatives of 2-acylamino-4-phenylthiazole, preparation method thereof and use of same as chemokine antagonists
WO2004096225A2 (en) * 2003-04-28 2004-11-11 Ab Science Use of tyrosine kinase inhibitors for treating cerebral ischemia
WO2006042954A1 (en) 2004-10-19 2006-04-27 Sanofi-Aventis 2-amido-4-phenylthiazole derivatives, the preparation and the therapeutic use thereof
WO2006067401A1 (en) 2004-12-24 2006-06-29 Astrazeneca Ab Heterocyclic compounds as ccr2b antagonists
WO2007077394A1 (en) 2006-01-06 2007-07-12 Sanofi-Aventis 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof

Patent Citations (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0001727A2 (en) 1977-10-19 1979-05-02 Pierre Fabre S.A. New derivatives of 4-phenyl-2-(2',2',2-trichlorethoxycarboxamido)-thiazole useful as medicaments, pharmaceutical compositions containing them and process for the preparation of these compounds
US4225610A (en) 1977-10-19 1980-09-30 Pierre Fabre, S.A. Immunoactivators derived from amino thiazoles
WO1987001706A2 (en) 1985-09-12 1987-03-26 The Upjohn Company C20 through c26 amino steroids
EP0518731A1 (en) 1991-06-05 1992-12-16 Sanofi Heterocyclic derivatives of substituted 2-acylamino 5-thiazole, their preparation and pharmaceutical compositions containing them
US5314889A (en) 1991-06-05 1994-05-24 Elf Sanofi Heterocyclic substituted 2-acylamino-5-thiazoles, their preparation and pharmaceutical compositions containing them
EP0519449A1 (en) 1991-06-21 1992-12-23 Boehringer Mannheim Italia S.P.A. 2-Amino-4-aryl thiazoles with antiasthmatic and antiinflammatory activities on the respiratory tract
WO1993000342A1 (en) 1991-06-21 1993-01-07 Boehringer Mannheim Italia S.P.A. 2-amino-4-aryl-thiazoles with antiasthmatic and anti-inflammatory activities on the respiratory tract
EP0611766A1 (en) 1993-02-19 1994-08-24 Sanofi Polysubstituted 2-amido thiazoles derivatives, process for their preparation, pharmaceutical compositions and utilization for the preparation of a medicament
WO1999015525A1 (en) 1997-09-19 1999-04-01 Sanofi-Synthelabo Carboxamidothiazole derivatives, preparation, pharmaceutical compositions containing them
US6506751B1 (en) 1999-11-12 2003-01-14 Millennium Pharmaceuticals, Inc. Thiazolidinone compounds useful as chemokine inhibitors
US20020119962A1 (en) 1999-12-17 2002-08-29 Jacobs Jeffrey W. Novel urea compounds, compositions and methods of use and preparation
US20020115863A1 (en) 1999-12-17 2002-08-22 Dinesh Patel Novel succinate compounds, compositions and methods of use and preparation
US20040048891A1 (en) 2000-12-22 2004-03-11 Fuminori Kato Aniline derivatives or salts thereof and cytokine production inhibitors containing the same
WO2002051397A1 (en) 2000-12-22 2002-07-04 Ishihara Sangyo Kaisha, Ltd. Aniline derivatives or salts thereof and cytokine production inhibitors containing the same
EP1344525A1 (en) 2000-12-22 2003-09-17 Ishihara Sangyo Kaisha, Ltd. Aniline derivatives or salts thereof and cytokine production inhibitors containing the same
WO2003015778A1 (en) * 2001-08-17 2003-02-27 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003057145A2 (en) 2001-12-31 2003-07-17 Guilford Pharmaceuticals Inc. SUBSTITUTED 4,9-DIHYDROCYCLOPENTA[imn]PHENANTHRIDINE-5-ONES DERIVATIVES THEREOF AND THEIR USES
WO2003088908A2 (en) 2002-04-19 2003-10-30 Bristol-Myers Squibb Company Heterocyclo inhibitors of potassium channel function
WO2003104230A1 (en) 2002-06-07 2003-12-18 協和醱酵工業株式会社 Bicyclic pyrimidine derivatives
WO2004096798A2 (en) 2003-04-25 2004-11-11 Sanofi-Aventis Derivatives of 2-acylamino-4-phenylthiazole, preparation method thereof and use of same as chemokine antagonists
US20060135575A1 (en) 2003-04-25 2006-06-22 Sanofi-Aventis 2-Acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
US7504511B2 (en) 2003-04-25 2009-03-17 Sanofi-Aventis 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
WO2004096225A2 (en) * 2003-04-28 2004-11-11 Ab Science Use of tyrosine kinase inhibitors for treating cerebral ischemia
WO2006042954A1 (en) 2004-10-19 2006-04-27 Sanofi-Aventis 2-amido-4-phenylthiazole derivatives, the preparation and the therapeutic use thereof
US20070259847A1 (en) 2004-10-19 2007-11-08 Sanofi-Aventis 2-Amido-4-phenylthiazole Derivatives, The Preparation And The Therapeutic Use Thereof
WO2006067401A1 (en) 2004-12-24 2006-06-29 Astrazeneca Ab Heterocyclic compounds as ccr2b antagonists
WO2007077394A1 (en) 2006-01-06 2007-07-12 Sanofi-Aventis 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
Abdel-Magid et al, Reductive Amination of Aldehydes and Ketones by Using Sodium Triacetoxyborohydride, Tetrahedron Letters, 1990 (31) 39 pp. 5595-5598.
Abdel-Magid et al, Reductive Amination of Aldehydes and Ketones with Sodium Triacetoxyborohydride. Studies on Direct and Indirect Reductive Amination Procedures, J. Org. Chem., 1996 (61) pp. 3849-3862.
Albini et al, A Rapid in Vitro Assay for Quantitating the Invasive Potential of Tumor Cells, Cancer Research, 1987 (47) pp. 3239-3245.
Allen et al, Discovery And SAR Of Trisubstituted Thiazolidinones As CCR4 Antagonists, Bioorganic & Medicinal Chemistry Letters, Apr. 2004, 14:1619-1624.
Byrn et al., Solid-State Chemistry of Drugs, Second Edition, 1999, pp. 233-247. *
Dolle et al, Synthesis and Antiviral Activity of 4-Benzyl Pyridinone Derivatives as Potent and Selective Non-Nucleoside Human Immunodeficiency Virus Type 1 Reverse Transcriptase Inhibitors, J. Med. Chem., 2000 (43) pp. 3949-3962.
Hudlicky et al, Synthesis of Dienic Acids. Application of Arndt-Eistert Reaction to Unsaturated Diazoketones, Tetrahedron Letters, 1979 (29) pp. 2667-2670.
Hudlicky et al, Synthesis of Dienic Acids. Application of Arndt—Eistert Reaction to Unsaturated Diazoketones, Tetrahedron Letters, 1979 (29) pp. 2667-2670.
Lombardino et al., Potent Antiinflammatory N-Heterocyclic 3-Carboxamides of 4-Hydroxy-2-methyl-2H-1,2-benzothiazine 1,1-Dioxide, J. Med. Chem., 16 (5) pp. 493-496 (1973).
Paavola et al, Monomeric Monocyte Chemoattractant Protein-1 (MCP-1) Binds and Activates the MCP-1 Receptor CCR2B, J. Bio. Chem., 1998 (273) 50 pp. 33157-33165.
Taylor et al, Novel 5-Desmethylene Analogues of 5,10-Dideaza-5,6,7,8-tetrahydrofolic Acid as Potential Anticancer Agents, J. Org. Chem., 1992 (57) pp. 3218-3225.
Taylor et al, Synthesis of Pyridines by Diels-Alder Reactions of Hetero-Substituted 1,2,4-Triazines with Enamines and an Enaminone, J. Org. Chem., 1989 (54) 6 pp. 1249-1256.
U.S. Appl. No. 12/146,898, filed Jun. 26, 2008, Fraisse.
U.S. Appl. No. 12/360,568, filed Jan. 27, 2009, Carayon.
Watson, Novel Methodology for the Preparation of 5-Substituted Tetrahydro[2,3-D]Pyrimidines, Synthetic Communications, 1998 (28) 10 pp. 1897-1905.

Also Published As

Publication number Publication date
CN101001847A (en) 2007-07-18
EA011076B1 (en) 2008-12-30
MA28734B1 (en) 2007-07-02
ECSP067110A (en) 2007-01-26
TNSN06439A1 (en) 2008-02-22
MX2007000367A (en) 2007-03-27
EA200700096A1 (en) 2007-06-29
FR2872813B1 (en) 2007-01-19
NO20070224L (en) 2007-04-02
ZA200700705B (en) 2008-06-25
ES2304719T3 (en) 2008-10-16
BRPI0513184A (en) 2008-04-29
AU2005271130A1 (en) 2006-02-16
EP1771425A1 (en) 2007-04-11
KR20070030271A (en) 2007-03-15
ATE395342T1 (en) 2008-05-15
IL180284A0 (en) 2007-07-04
DE602005006815D1 (en) 2008-06-26
JP2008505872A (en) 2008-02-28
CA2571143A1 (en) 2006-02-16
PE20060487A1 (en) 2006-07-06
CR8824A (en) 2007-08-28
US20070179126A1 (en) 2007-08-02
FR2872813A1 (en) 2006-01-13
WO2006016039A1 (en) 2006-02-16
UY29007A1 (en) 2006-02-24
EP1771425B1 (en) 2008-05-14
TW200621737A (en) 2006-07-01
AR054397A1 (en) 2007-06-27

Similar Documents

Publication Publication Date Title
US7767681B2 (en) 2-Carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
US7504511B2 (en) 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
US7598392B2 (en) 2-amido-4-phenylthiazole derivatives, the preparation and the therapeutic use thereof
US9156839B2 (en) Fused bicyclic sulfamoyl derivatives and the use thereof as medicaments for the treatment of hepatitis B
US7615550B2 (en) Substituted piperazines,(1,4) diazepines, and 2,5-diazabicyclo (2.2.1)iieptanes as histamine H1 and/or H3 antagonists or histamine H3 reverse antagonists
US8962609B2 (en) Pyrimidine compounds as inhibitors of protein kinases IKK epsilon and/or TBK-1, processes for their preparation, and pharmaceutical compositions containing them
US8912218B2 (en) Alkylthiazol carbamate derivatives, preparation thereof and therapeutic use thereof
US20080242677A1 (en) Imidazolidinone derivatives
US20100144712A1 (en) Triazole derivatives having antifungal activity, method for the preparation thereof, and pharmaceutical composition comprising the same
US7618991B2 (en) Heterocyclic derivatives, preparation and therapeutic use thereof
JP6095195B2 (en) New bicyclic thiazole compounds
US7825112B2 (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
US20050192289A1 (en) Novel cinnamic amides

Legal Events

Date Code Title Description
AS Assignment

Owner name: SANOFI-AVENTIS, FRANCE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CASELLAS, PIERRE;FLOUTARD, DANIEL;FRAISSE, PIERRE;AND OTHERS;REEL/FRAME:019068/0746

Effective date: 20070309

CC Certificate of correction
REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20140803